Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
  • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
  • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/545—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

• the present invention relates to novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel benzodiazepine compounds derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents.
• Benzodiazepine derivatives are useful compounds for treating various disorders, and include medicaments such as, antiepileptics (imidazo [2,l-b] [l,3,5]
• benzothiadiazepines U.S. Pat. No. 4,444,688; U.S. Pat. No. 4,062,852
• antibacterials pyrimido[l,2-c] [l,3,5]benzothiadiazepines, GB 1476684
• diuretics and hypotensives pyrrolo(l,2-b)[l,2,5]benzothiadiazepine 5,5 dioxide, U.S. Pat. No. 3,506,646)
• hypolipidemics WO 03091232
• anti-depressants U.S. Pat. No. 3,453,266);
• benzodiazepine derivatives such as pyrrolobenzodiazepines (PBDs)
• PBDs pyrrolobenzodiazepines
• Benzodiazepines are also known to affect cell growth and differentiation (Kamal A., et al, Bioorg Med Chem. 2008 Aug 15; 16(16):7804-10 (and references cited therein); Kumar R, Mini Rev Med Chem. 2003 Jun;3(4):323-39 (and references cited therein); Bednarski J J, et al, 2004; Sutter A. P, et al, 2002; Blatt N B, et al, 2002), Kamal A. et al, Current Med. Chem., 2002; 2; 215-254, Wang J-J., J.Med. Chem., 2206; 49: 1442- 1449, Alley M.C. et al, Cancer Res. 2004; 64:6700-6706, Pepper C. J., Cancer Res 2004; 74:6750-6755, Thurston D.E. and Bose D.S., Chem Rev 1994;
• PBDs General structure of PBDs is described in US Publication Number 20070072846.
• the PBDs differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. Their ability to form an adduct in the minor groove and crosslink DNA enables them to interfere with DNA processing, hence their potential for use as antiproliferative agents.
• SJG-136 (NSC 694501) is a potent cytotoxic agent that causes DNA inter-strand crosslinks (S.G Gregson et al, 2001, /. Med. Chem., 44: 737-748; M.C. Alley et al, 2004, Cancer Res., 64: 6700-6706; J.A. Hartley et al, 2004, Cancer Res., 64: 6693-6699; C. Martin et al, 2005,
• Cytotoxic benzodiazepine dimers disclosed in the art possess two imine functionalities in their free form or reversibly protected form, such as a hydrate, alkoxylate or sulfonate. The presence of these two imine functionalities results in crosslinking of DNA (S.G. Gregson et al, 2001, /. Med. Chem., 44: 737-748).
• the present invention is partly based on the unexpected finding that cell binding agent conjugates of new cytotoxic benzodiazepine derivatives, such as
• indolinobenzodiazapene dimers that are devoid of two imine functionalities ⁇ e.g. , one imine functionality and one amine functionality), and thus incapable of crosslinking DNA, display a much higher therapeutic index (ratio of maximum tolerated dose to minimum effective dose) in vivo compared to benzodiazepine derivatives that can crosslink DNA that are previously disclosed in the art.
• one object of the invention is to provide cytotoxic compound comprising a linking group with a reactive group bonded thereto capable of covalently linking the cytotoxic compound to a cell binding agent (CBA, see below), wherein the cytotoxic compound is re resented by any one of the following formulas:
• Y is -H or a leaving group selected from -OR, -OCOR', -OCOOR', - OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5 or 6-membered nitrogen-containing heterocycle (e.g.
• Y is a sulfite (HS0 3 , HS0 2 or a salt of HS0 3 " , S0 3 2" or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 0 5 or a salt of S 2 0 5 " formed with a cation), mono-, di-, tri-, and tetra- thiophosphate (PO 3 SH 3 , P0 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 or a salt of PO 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate ester (R ⁇ PSfOR 1 ), R ; S-, R ; SO, R ; S0 2 , R ⁇ Os, thiosulfate (HS 2 0 3 or a salt of
• M is -H or a cation
• R for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• R' and R' ' are each independently selected from -H, -OH, -OR, -NHR, - NR 2 , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
• R c is -H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms, or the linking group with the reactive group bonded thereto; n is an integer from 1 to 24;
• X' is selected from -H, an amine-protecting group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• Y' is selected from -H, an oxo group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3 to 18-membered heterocyclic ring having 1 to 6 heteroatoms;
• R 6 is -H, -R, -OR, -SR, -NR'R", -N0 2 , halogen or the linking group with the reactive group bonded thereto;
• R 7 and Rg are the same or different, and are each independently selected from -H, -OH, -SH, -COOH, -NHR', a polyethylene glycol unit -(OCH 2 CH 2 ) n -, an amino acid, a peptide unit bearing 2 to 6 amino acids, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms;
• Rg is independently selected from -H, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH 2 CH 2 ) n -;
• R5 for each occurrence is independently -H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
• D and D' are the same or different, and are independently absent or selected from the group consisting of an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, an amino acid, a peptide bearing 2 to 6 amino acids, and a polyethylene glycol unit (-OCH 2 CH 2 ) n -
• L is absent, the linking group with the reactive group bonded thereto, a polyethylene glycol unit (-OCH 2 CH 2 ) n -, a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3 to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P, wherein the alkyl or alkenyl is optionally substituted with the linking group with the reactive group bonded thereto; phenyl or heterocyclic or heteroaryl ring can be optionally substituted, wherein the substituent can be the linking group with the reactive group bonded thereto.
• X is not the linking group with the reactive group bonded thereto.
• the double line— between N and C represents a single bond, Y is not -H.
• the compound is not any one of the following compounds:
• Y is a leaving group selected from -OR, -OCOR' , - OCOOR', -OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g.
• an amino acid or a peptide represented by -NRCOP'
• P' is an amino acid or a polypeptide containing between 2 to 20 amino acid units, -SR, -SOR' , -S0 2 M, -SO 3 M, - OSO 3 M, halogen, cyano and an azido.
• a second object of the invention is to provide conjugates of cell binding agents with the novel benzodiazepine compounds or derivatives thereof of the present invention. These conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic.
• a conjugate of the invention may comprise: a cytotoxic compound and a cell binding agent (CBA), wherein the cytotoxic compound comprises a linking group which covalently links the cytotoxic compound to the CBA, and wherein the cytotoxic compound is represented by any one of the following formulas:
• Y is -H or a leaving group selected from -OR, -OCOR', -OCOOR' , - OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5 or 6-membered nitrogen-containing heterocycle (e.g.
• an amino acid or a peptide represented by -NRCOP'
• P' is an amino acid or a polypeptide containing between 2 to 20 amino acid units, -SR, -SOR', - S0 2 M, -SO 3 M, -OSO 3 M, halogen, cyano and an azido; or,
• Y is a sulfite (HS0 3 , HS0 2 or a salt of HS0 3 " , S0 3 2 ⁇ or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 O 5 or a salt of S 2 O 5 " formed with a cation), mono-, di-, tri-, and tetra- thiophosphate (PO 3 SH 3 , P0 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 or a salt of PO 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate ester (R ⁇ PSfOR 1 ), R ; S-, R ; SO, ⁇ 80 2 , R ⁇ Os, thiosulfate (HS 2 0 3 or a salt of 2- " formed with a cation), dithionite 2 O 4 or a salt of S 2 0 4 2-
• R 1 is a linear or branched alkyl having 1 to 10 carbon atoms and is substituted with at least one substituent selected from -N(R j ) 2 , -C0 2 H, -SO 3 H, and -PO 3 H; R' can be further optionally substituted with a substituent for an alkyl described herein;
• R J is a linear or branched alkyl having 1 to 6 carbon atoms;
• M is -H or a cation
• R for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• R' and R' ' are each independently selected from -H, -OH, -OR, -NHR, - NR 2 , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
• R c is -H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms, or the linking group;
• n is an integer from 1 to 24;
• X' is selected from -H, an amine-protecting group, the linking group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• Y' is selected from -H, an oxo group, the linking group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3 to 18-membered heterocyclic ring having 1 to 6 heteroatoms;
• R 6 is -H, -R, -OR, -SR, -NR'R", -N0 2 , halogen or the linking group;
• Z and Z' are independently selected from -(CH 2 ) n '-, -(CH 2 ) n --CR 7 R8- (CH 2 ) na -, -(CH 2 V-NR 9 -(CH 2 ) na -, -(CH 2 ) n -0-(CH 2 ) na - and -(CH 2 ) n -S-(CH 2 ) na -; n' and na' are the same or different, and are selected from 0, 1, 2 and 3;
• R 7 and Rg are same or different, and are each independently selected from -H, -OH, -SH, -COOH, -NHR', a polyethylene glycol unit -(OCH 2 CH 2 ) n -, an amino acid, a peptide unit bearing 2 to 6 amino acids, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms;
• R9 is independently selected from -H, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH 2 CH 2 ) n -;
• D and D' are the same or different, and are independently absent or selected from the group consisting of an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, an amino acid, a peptide bearing 2 to 6 amino acids, and a polyethylene glycol unit (-OCH 2 CH 2 ) n -
• L is absent, the linking group, a polyethylene glycol unit (-OCH 2 CH 2 ) n -, a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3- to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P, wherein the alkyl or alkenyl is optionally substituted with the linking group; phenyl or heterocyclic or heteroaryl ring can be optionally substituted, wherein the substituent can be the linking group.
• a polyethylene glycol unit (-OCH 2 CH 2 ) n - a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3- to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1
• X is not the linking group.
• Y is -H or a leaving group selected from -OR, -OCOR' , -OCOOR' , -OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g.
• Y is not -H.
• the compound of the conjugate is not any one of the following compounds (the wavy bond represents the bond through which the compound is linked to the CB
• the present invention also includes a composition (e.g. , a pharmaceutical composition) comprising novel benzodiazepine compounds, derivatives thereof, or conjugates thereof, (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically acceptable carrier).
• a composition e.g. , a pharmaceutical composition
• the present invention additionally includes a composition (e.g. , a pharmaceutical composition) comprising novel benzodiazepine compounds, derivatives thereof, or conjugates thereof (and/or solvates, hydrates and/or salts thereof), and a carrier (a pharmaceutically acceptable carrier), further comprising a second therapeutic agent.
• the present compositions are useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g. , human).
• compositions are useful for treating conditions such as cancer, rheumatoid arthritis, multiple sclerosis, graft versus host disease (GVHD), transplant rejection, lupus, myositis, infection, immune deficiency such as AIDS, and inflammatory diseases in a mammal (e.g. , human).
• conditions such as cancer, rheumatoid arthritis, multiple sclerosis, graft versus host disease (GVHD), transplant rejection, lupus, myositis, infection, immune deficiency such as AIDS, and inflammatory diseases in a mammal (e.g. , human).
• the present invention includes a method of inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g. , human) comprising administering to said mammal a therapeutically effective amount of novel benzodiazepine compounds, derivatives thereof, or conjugates thereof, (and/or solvates and salts thereof) or a composition thereof, alone or in combination with a second therapeutic agent.
• a mammal e.g. , human
• the present invention includes a method of synthesizing and using novel benzodiazepine compounds, derivatives thereof, and conjugates thereof for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
• the compounds of this invention, derivatives thereof, or conjugates thereof, and compositions comprising them, are useful for treating or lessening the severity of disorders, such as, characterized by abnormal growth of cells (e.g. , cancer).
• Other applications for compounds and conjugates of this invention include, but are not limited to, treating conditions such as cancer, rheumatoid arthritis, multiple sclerosis, graft versus host disease (GVHD), transplant rejection, lupus, myositis, infection, immune deficiency such as AIDS and inflammatory diseases in a mammal (e.g. , human).
• FIGS. 1-6 show the schemes for the synthesis of benzodiazepine compounds and the corresponding linkable compounds suitable for conjugation of the present invention.
• FIG. 7 shows the scheme for the synthesis of representative compounds with PEG modified linkers of the present invention.
• FIG. 8 shows the scheme for the synthesis of representative compounds with a methylthio linker of the present invention.
• FIGS. 9-10 show the schemes for the synthesis of representative compounds containing a tertiary amine of the present invention.
• FIG. 11 shows the scheme for the synthesis of representative compounds with a peptide linker of the present invention.
• FIGS. 12-19 show the schemes for the synthesis of representative compounds suitable for one-step conjugation methods of the present invention.
• FIG. 20 shows the scheme for a two-step mono-imine dimer synthesis.
• FIG. 21 shows the scheme for a two-step di-reduced dimer synthesis.
• FIG. 22 shows the scheme for the one-step synthesis of the representative antibody-drug conjugates.
• FIG. 23 shows the scheme for the two-step synthesis of the representative antibody-drug conjugates.
• FIG. 24 shows the in vitro cytotoxicity of the methyldithio dimer Id against Namalwa, KB and HL60/QC cell lines.
• FIG. 25 shows the in vitro cytotoxicity and specificity of the huMy9-6-SPDB-lf conjugates against various cell lines. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 26 shows the in vitro cytotoxicity and specificity of the huFOLRl-SPDB-lf conjugates.
• FIG. 27 shows conjugation of dimer does not reduce binding affinity of antibody. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 28 shows the in vivo antitumor activity of huMy9-6 conjugate. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 29 shows in vitro cytotoxicity of huMy9-6-SPDB-lf conjugate against antigen positive cells. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 30 shows synthetic scheme for making thioether-containing linker disulfides 27e-h.
• FIG. 31 shows synthetic scheme for making dimers 28c-f.
• FIG. 32 shows synthetic scheme for making phenyl linked dimers 29b-c.
• FIG. 33 shows the scheme for an alternative two-step synthesis for mono-imine dimers.
• FIG. 34 shows in vitro cytotoxicity for huMy9-6-SPDB-lf (A), huMy9-6- sulfoSPDB-lf (B) and huMy9-6-BMPS-lf (C) against HL60/QC (Ag + ) cells with and without blocking of antigen binding sites. Note that in all three experiments (34A, 34B, and 34C), sodium bisulfite were added to the conjugation reaction for making the conjugate.
• FIG. 35 shows in vitro cytotoxicity for chB38.1-SPDB-lf (A), and chB38.1- sulfoSPDB-lf (B) against COLO205 (Ag + ) cells. Note that in both experiments, sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 36 shows in vivo efficacy of huMy9-6-SPDB-lf in HL60/QC bearing mice.
• FIG. 37 shows in vivo efficacy of huFOLRl-SPDB-lf in KB tumor bearing mice.
• FIG. 38 shows synthetic scheme of compound 1.
• FIG. 39 shows a synthetic scheme of compound Id with 5-ethyl-2- methylpyridine borane (PEMB).
• FIG. 40 shows a synthetic scheme of compound Id with sodium
• FIG. 41 shows a synthetic scheme of compound 31a-c.
• FIG. 42 shows a synthetic scheme of compound 32c,d.
• FIG. 43 shows a synthetic scheme of compounds li and 12a.
• FIG. 44 shows antiproliferative activity by comparing (A) huMy9-6-SPDB-lf,
• FIG. 45 shows an alternate scheme for synthesizing 4-(benzyloxy)-5-methoxy-2- nitrobenzoic acid used in the preparation of IBD monomer.
• FIG. 46 is an alternate synthesis scheme for (5-((2-(2-(2- methoxyethoxy)ethoxy)ethyl)(2-methyl-2-(methyldisulfanyl)propyl)amino)-l,3- phenylene)dimethanol (lb).
• FIG. 47 is an alternate synthesis scheme for (5-((2-(2-(2- methoxyethoxy)ethoxy)ethyl)(2-methyl-2-(methyldisulfanyl)propyl)amino)-l,3- phenylene)dimethanol (lb).
• FIG. 48 is an alternate synthetic scheme for a two-step mono-imine dimer synthesis.
• FIG. 49 shows potency of various conjugates against various cell lines.
• the IC 50 values listed in the table are in the unit of nM.
• FIG. 50 shows in vivo efficacy of huMy9-6-sulfo-SPDB-lf in MOLM-13 tumor bearing mice.
• FIG. 51 shows in vivo efficacy of huMy9-6-sulfo-SPDB-lf in NB4 tumor bearing mice.
• FIG. 52 shows in vivo efficacy of huMy9-6-BMPS-lf in HL60/QC tumor bearing mice.
• FIG. 53 shows in vivo efficacy of huMy9-6-BMPS-lf in MOLM-13 tumor bearing mice. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 54 shows a representative synthesis scheme for a Sulfonated folate / cytotoxic compound conjugate.
• FIG. 55 shows several representative sulfonated drug-antibody conjugates with different linkers.
• FIG. 56 shows in vivo efficacy of huMy9-6-Drug 2 in HL60/QC tumor bearing mice. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 57 shows in vivo efficacy of huMy9-6-Drug 2 in MOLM-13 tumor bearing mice. Note that sodium bisulfite was added to the conjugation reaction for making the conjugate.
• FIG. 58 shows similar in vitro cytotoxicity of HuMy9-6-Drug 2 (conjugates prepared without and with sodium bisulfite against CD33-antigen expressing HL60 cells.
• FIG. 59 shows similar in vitro cytotoxicity of anti-CD22 Ab-Drug 2 conjugates prepared without and with sodium bisulfite against CD22-antigen expressing BJAB cells.
• FIG. 60 shows the preparation of huMy9-6-sulfo-SPDB-ld using the highly reactive 4-nitroPy-sulfo-SPDB linker.
• Linear or branched alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical of one to twenty carbon atoms.
• alkyl examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1- butyl, 2-methyl-l -propyl, -CH 2 CH(CH 3 )2), 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2- pentyl 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-l -butyl, 2-methyl-l- butyl, 1-hexyl), 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2- pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2- butyl, 1-heptyl, 1-octyl, and the like.
• the alkyl has one to ten carbon atoms. More preferably, the alkyl,
• the alkenyl has two to ten carbon atoms. More preferably, the alkyl has two to four carbon atoms.
• Linear or branched alkynyl refers to a linear or branched monovalent hydrocarbon radical of two to twenty carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, triple bond. Examples include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, hexynyl, and the like.
• the alkynyl has two to ten carbon atoms. More preferably, the alkynyl has two to four carbon atoms.
• carrier refers to a monovalent non-aromatic, saturated or partially unsaturated ring having 3 to 12 carbon atoms as a monocyclic ring or 7 to 12 carbon atoms as a bicyclic ring.
• Bicyclic carbocycles having 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5], [5,5], [5,6], or [6,6] system, and bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a bicyclo [5,6] or [6,6] system, or as bridged systems such as
• bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1- cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
• cyclic alkyl and “cycloalkyl” can be used interchangeably. They refer to a monovalent saturated carbocyclic ring radical. Preferably, the cyclic alkyl is 3 to 7 membered monocyclic ring radical. More preferably, the cyclic alkyl is cyclohexyl.
• cyclic alkenyl refers to a carbocyclic ring radical having at least one double bond in the ring structure.
• cyclic alkynyl refers to a carbocyclic ring radical having at least one triple bond in the ring structure.
• Aryl means a monovalent aromatic hydrocarbon radical of 6-18 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Some aryl groups are represented in the exemplary structures as "Ar.” Aryl includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
• Typical aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzenes, naphthalene, anthracene, indenyl, indanyl, 1,2-dihydronapthalene, 1,2,3,4-tetrahydronapthyl, and the like.
• aryl is phenyl group.
• heterocycle refers to a saturated or a partially unsaturated (i.e., having one or more double and/or triple bonds within the ring) carbocyclic radical of 3 to 18 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, the remaining ring atoms being C, where one or more ring atoms is optionally substituted independently with one or more substituents described below.
• a heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
• Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of
• Heterocyclic Compounds A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.
• Heterocyclyl also includes radicals where heterocycle radicals are fused with a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
• heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolan
• azabicyclo[2.2.2]hexanyl Spiro moieties are also included within the scope of this definition.
• heteroaryl refers to a monovalent aromatic radical of 5- or 6- membered rings, and includes fused ring systems (at least one of which is aromatic) of 5-18 atoms, containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur.
• heteroaryl groups are pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl,
• the heterocycle or heteroaryl groups may be carbon (carbon-linked) or nitrogen (nitrogen-linked) attached where such is possible.
• carbon bonded heterocycles or heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4,
• nitrogen bonded heterocycles or heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2- pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H- indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or O-carboline.
• heteroatoms present in heteroaryl or heterocyclcyl include the oxidized forms such as NO, SO, and S0 2 .
• halo or halogen refers to F, CI, Br or I.
• alkyl, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl described above can be optionally substituted with one more (e.g. , 2, 3, 4, 5, 6 or more) substituents.
• a substituent is described as being "substituted," a non-hydrogen substituent is in the place of a hydrogen substituent on a carbon, oxygen, sulfur or nitrogen of the substituent.
• a substituted alkyl substituent is an alkyl substituent wherein at least one non-hydrogen substituent is in the place of a hydrogen substituent on the alkyl substituent.
• monofluoroalkyl is alkyl substituted with a fluoro substituent
• difluoroalkyl is alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one substitution on a substituent, each non- hydrogen substituent may be identical or different (unless otherwise stated).
• a substituent is described as being “optionally substituted,” the substituent may be either (1) not substituted, or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the carbon (to the extent there are any) may separately and/or together be replaced with an independently selected optional substituent. If a nitrogen of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the nitrogen (to the extent there are any) may each be replaced with an independently selected optional substituent.
• One exemplary substituent may be depicted as -NR'R", wherein R' and R" together with the nitrogen atom to which they are attached, may form a heterocyclic ring.
• heterocyclic ring formed from R' and R" together with the nitrogen atom to which they are attached may be partially or fully saturated.
• the heterocyclic ring consists of 3 to 7 atoms.
• the heterocyclic ring is selected from the group consisting of pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, pyridyl and thiazolyl.
• a group of substituents are collectively described as being optionally substituted by one or more of a list of substituents, the group may include: (1) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) substitutable substituents that are substituted by one or more of the optional substituents.
• a substituent is described as being optionally substituted with up to a particular number of non-hydrogen substituents, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less.
• a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen substituents, then any heteroaryl with less than 3
• substitutable positions would be optionally substituted by up to only as many non- hydrogen substituents as the heteroaryl has substitutable positions.
• substituents independently selected from halogen, -OH, -CN, -N0 2 and unsubstituted linear or branched alkyl having 1 to 4 carbon atoms.
• substituents for the optionally substituted alkyl, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl described above include halogen, -CN, -NR 102 R 103 , -CF 3 , -OR 101 , aryl, heteroaryl, heterocycycl, -SR 101 , - SOR 101 , -S0 2 R 101 and -S0 3 M.
• cytotoxic dimer compound are used interchangeably. They are intended to include compounds for which a structure or formula or any derivative thereof has been disclosed in the present invention or a structure or formula or any derivative thereof that has been incorporated by reference.
• the term also includes, stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts (e.g. , pharmaceutically acceptable salts) and prodrugs, and prodrug salts of a compound of all the formulae disclosed in the present invention.
• the term also includes any solvates, hydrates, and polymorphs of any of the foregoing.
• conjugate refers to a compound described herein or a derivative thereof that is linked to a cell binding agent.
• linkable to a cell binding agent refers to the compounds described herein or derivates thereof comprising at least one linking group or a precursor thereof suitable to bond these compounds or derivatives thereof to a cell binding agent.
• precursor of a given group refers to any group which may lead to that group by any deprotection, a chemical modification, or a coupling reaction.
• linked to a cell binding agent refers to a conjugate molecule comprising at least one of the compounds described herein (e.g. , compounds of formula (I)- (IV) and (VIII)-(XI) and drug-linker compounds describe herein), or derivative thereof bound to a cell binding agent via a suitable linking group or a precursor thereof.
• stereoisomer refers to compounds which have identical chemical constitution and connectivity, but different orientations of their atoms in space that cannot be interconverted by rotation about single bonds.
• Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as crystallization, electrophoresis and chromatography.
• Enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
• the compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
• Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s).
• d and I or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
• a compound prefixed with (+) or d is dextrorotatory.
• these stereoisomers are identical except that they are mirror images of one another.
• a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
• a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
• racemic mixture and racemate refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
• tautomer or "tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
• proton tautomers also known as prototropic tautomers
• Valence tautomers include interconversions by reorganization of some of the bonding electrons.
• prodrug refers to a precursor or derivative form of a compound of the invention that is capable of being enzymatically or hydrolytically activated or converted into the more active parent form. See, e.g., Wilman, "Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Harbor (1986) and Stella et al, "Prodrugs: A Chemical
• the prodrugs of this invention include, but are not limited to, ester-containing prodrugs, phosphate-containing prodrugs, thiophosphate- containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, ⁇ -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs, optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug.
• cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, compounds of the invention and chemotherapeutic agents such as described above.
• prodrug is also meant to include a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide a compound of this invention. Prodrugs may only become active upon such reaction under biological conditions, or they may have activity in their unreacted forms.
• prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of any one of the formulae disclosed herein that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
• Other examples of prodrugs include derivatives of compounds of any one of the formulae disclosed herein that comprise - NO, -N0 2 , -ONO, or -ON0 2 moieties.
• Prodrugs can typically be prepared using well- known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5th ed); see also Goodman and Oilman' s, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs.”
• prodrug of the invention includes compounds (with or without any linker groups) and conjugates of the invention comprising an adduct formed between an imine bond of the compounds / conjugates and an imine reactive reagent.
• Another preferred form of prodrug of the invention includes compounds such as those of formula (I) - (IV), wherein when the double line ⁇ between N and C represents a single bond, X is H or an amine protecting group, and the compound becomes a prodrug.
• a prodrug of the invention may contain one or both forms of prodrugs described herein (e.g. , containing an adduct formed between an imine bond of the compounds / conjugates and an imine reactive reagent, and/or containing a Y leaving group when X is -H).
• imine reactive reagent refers to a reagent that is capable of reacting with an imine group.
• imine reactive reagent includes, but is not limited to, sulfites (H 2 S0 3 , H 2 S0 2 or a salt of HS0 3 " , S0 3 2" or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 0s or a salt of S 2 0 5 " formed with a cation), mono, di, tri, and tetra- thiophosphates (P0 3 SH 3 , P0 2 S 2 H 3 , POS 3 H 3 , PS 4 H 3 or a salt of P0 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate esters ((P O ⁇ PS OR 1 ), PJSH, P SOH, R'SO ⁇ , R'SOsH), various phosphate esters ((
• HOCH 2 S0 2 " formed with a cation, such as HOCH 2 S0 2 " Na + ), glycated nucleotide (such as GDP-mannose), fludarabine or a mixture thereof, wherein R 1 and R 1 are each independently a linear or branched alkyl having 1 to 10 carbon atoms and are substituted with at least one substituent selected from -N(R j ) 2 , -C0 2 H, -S0 3 H, and -P0 3 H; R' and R r can be further optionally substituted with a substituent for an alkyl described herein; R J is a linear or branched alkyl having 1 to 6 carbon atoms; and R k is a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, aryl, heterocyclyl or heteroaryl (preferably, R k is a linear or branched alkyl having 1 to 4 carbon
• the cation is a monovalent cation, such as Na + or K + .
• the imine reactive reagent is selected from sulfites, hydroxyl amine, urea and hydrazine. More preferably, the imine reactive reagent is NaHS0 3 or KHS0 3 .
• biohydrolyzable amide As used herein and unless otherwise indicated, the terms “biohydrolyzable amide,” “biohydrolyzable ester,” “biohydrolyzable carbamate,” “biohydrolyzable carbonate,” “biohydrolyzable ureide” and “biohydrolyzable phosphate analogue” mean an amide, ester, carbamate, carbonate, ureide, or phosphate analogue, respectively, that either: 1) does not destroy the biological activity of the compound and confers upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is itself biologically inactive but is converted in vivo to a biologically active compound.
• biohydrolyzable amides include, but are not limited to, lower alkyl amides, a-amino acid amides, alkoxyacyl amides, and
• alkylaminoalkylcarbonyl amides examples include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
• biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, amino acids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
• Particularly favored prodrugs and prodrug salts are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal.
• salts refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention.
• Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate,” ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., l,l'-methylene-
• a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion.
• the counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
• a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
• the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid,
• hydrobromic acid sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p- toluenesulfonic acid or ethanesulfonic acid, or the like.
• an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid
• the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
• an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
• suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
• amino acids such as glycine and arginine
• ammonia such as glycine and arginine
• primary, secondary, and tertiary amines such as piperidine, morpholine and piperazine
• inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
• solvate means a compound which further includes a stoichiometric or non- stoichiometric amount of solvent such as water, isopropanol, acetone, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine dichloromethane, 2-propanol, or the like, bound by non-covalent intermolecular forces.
• Solvates or hydrates of the compounds are readily prepared by addition of at least one molar equivalent of a hydroxylic solvent such as methanol, ethanol, 1-propanol, 2- propanol or water to the compound to result in solvation or hydration of the imine moiety.
• abnormal cell growth and “proliferative disorder” are used interchangeably in this application.
• abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g. , loss of contact inhibition).
• tumor cells tumor cells
• tumors tumor cells
• any tumors that proliferate by receptor tyrosine kinases any tumors that proliferate by aberrant serine/threonine kinase activation
• benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs.
• cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
• tumor comprises one or more cancerous cells, and/or benign or pre-cancerous cells.
• cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. , epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer (“NSCLC”),
• NSCLC non-small cell lung cancer
• adenocarcinoma of the lung and squamous carcinoma of the lung cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, acute leukemia, head/brain and neck cancer, cancers of lymphatic organs and hematological malignancy including Leukemia (Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic lymphocytic leukemia (CLL), Chronic myelogenous leukemia (CML), Acute monocytic leukemia (AMOL), Hairy cell leukemia (HCL), T-cell prolymp
• Lymphocyte depleted or not depleted Lymphocyte depleted or not depleted
• Nodular lymphocyte -predominant Hodgkin lymphoma Non-Hodgkin's lymphomas (all subtypes)
• Chronic lymphocytic leukemia/Small lymphocytic lymphoma B-cell prolymphocytic leukemia
• Lymphoplasmacytic lymphoma such as Waldenstrom macroglobulinemia
• Splenic marginal zone lymphoma Plasma cell neoplasms
• Plasma cell neoplasms Plasma cell neoplasms (Plasma cell myeloma, Plasmacytoma, Monoclonal immunoglobulin deposition diseases, Heavy chain diseases), Extranodal marginal zone B cell lymphoma (MALT lymphoma), Nodal marginal zone B cell lymphoma (NMZL), Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma, Mediastinal (thymic) large B cell lymphoma, Intravascular large B cell lymphoma, Primary effusion lymphoma, Burkitt lymphoma/leukemia, T cell
• prolymphocytic leukemia T cell large granular lymphocytic leukemia, Aggressive NK cell leukemia, Adult T cell leukemia/lymphoma, Extranodal NK/T cell lymphoma (nasal type), Enteropathy-type T cell lymphoma, Hepatosplenic T cell lymphoma, Blastic NK cell lymphoma, Mycosis fungoides / Sezary syndrome, Primary cutaneous CD30- positive T cell lymphoproliferative disorders, Primary cutaneous anaplastic large cell lymphoma, Lymphomatoid papulosis, Angioimmunoblastic T cell lymphoma, Peripheral T cell lymphoma (unspecified), Anaplastic large cell lymphoma), multiple myeloma (plasma cell myeloma or Kahler's disease).
• a "therapeutic agent” encompasses both a biological agent such as an antibody, a peptide, a protein, an enzyme or a chemotherapeutic agent.
• a "chemotherapeutic agent” is a chemical compound useful in the treatment of cancer.
• chemotherapeutic agents include Erlotinib (TARCEVA®,
• triethylenemelamine triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine
• acetogenins especially bullatacin and bullatacinone
• camptothecin including the synthetic analog topotecan
• bryostatin including the synthetic analog topotecan
• callystatin including its adozelesin, carzelesin and bizelesin synthetic analogs
• cryptophycins particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CBl-TMl); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.
• calicheamicin especially calicheamicin gammall and calicheamicin omegall (Angew Chem. Intl. Ed. Engl. (1994) 33: 183-186); dynemicin, including dynemicin A;
• bisphosphonates such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores),
• aclacinomysins actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® (doxorubicin), morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and
• deoxydoxorubicin epirubicin
• esorubicin idarubicin
• marcellomycin mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin
• anti-metabolites such as methotrexate and 5- fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamniprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, eno
• mitoguazone mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2' ,2"-trichlorotriethylamine;
• trichothecenes especially T-2 toxin, verracurin A, roridin A and anguidine
• urethan vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
• TAXOL® paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N.J.
• NAVELBINE® (vinorelbine); novantrone; teniposide; edatrexate; daunomycin;
• aminopterin capecitabine (XELODA®); ibandronate; CPT-11 ; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above.
• chemotherapeutic agent also included in the definition of "chemotherapeutic agent” are: (i) anti- hormonal agents that act to regulate or inhibit hormone action on tumors such as anti- estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, 4- hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)- imidazoles, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN®
• SERMs selective estrogen receptor modulators
• ribozymes such as VEGF expression inhibitors (e.g. , ANGIOZYME®) and HER2 expression inhibitors
• vaccines such as gene therapy vaccines, for example, ALLOVECTIN®,
• LEUVECTIN®, and VAXID® PROLEUKIN® rIL-2; a topoisomerase 1 inhibitor such as LURTOTECAN®; ABARELIX® rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTIN®, Genentech); and (x) pharmaceutically acceptable salts, acids and derivatives of any of the above.
• Other anti-angiogenic agents include MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, COX-II (cyclooxygenase II) inhibitors, and VEGF receptor tyrosine kinase inhibitors.
• VEGF receptor tyrosine kinase inhibitors include 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(l-methylpiperidin-4- ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2- methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-l-ylpropoxy)-quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SU11248 (sunitinib; WO 01/60814), and compounds such as those disclosed in PCT Publication Nos. WO 97/22596, WO 97/30035, WO 97/32856, and WO 98/133
• chemotherapeutic agents that can be used in combination with the present compounds include inhibitors of PI3K (phosphoinositide-3 kinase), such as those reported in Yaguchi et al (2006) Jour, of the Nat. Cancer Inst. 98(8):545-556; U.S. Pat. No. 7,173,029; U.S. Pat. No. 7,037,915; U.S. Pat. No. 6,608,056; U.S. Pat. No. 6,608,053; U.S. Pat. No. 6,838,457; U.S. Pat. No. 6,770,641; U.S. Pat. No. 6,653,320; U.S. Pat. No. 6,403,588; WO 2006/046031; WO 2006/046035; WO 2006/046040; WO 2007/042806; WO 2007/042810; WO 2004/017950; US 2004/092561; WO
• PI3K inhibitors include SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis, Inc.).
• Chemotherapeutic agents may also include any of the generic drugs or biosimilars of the brand-name drugs referenced herein, or improvements thereof, including improved formulations, prodrugs, delivery means (sustained release, bioadhesive coating, targeted delivery etc.), and dosage forms.
• a “metabolite” is a product produced through metabolism in the body of a specified compound, a derivative thereof, or a conjugate thereof, or salt thereof.
• Metabolites of a compound, a derivative thereof, or a conjugate thereof may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from the oxidation, hydroxylation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
• the invention includes metabolites of compounds, a derivative thereof, or a conjugate thereof, of the invention, including compounds, a derivative thereof, or a conjugate thereof, produced by a process comprising contacting a compound, a derivative thereof, or a conjugate thereof, of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
• phrases "pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
• protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound, a derivative thereof, or a conjugate thereof.
• an "amine-protecting group” or an “amino-protecting moiety” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
• Such groups are well known in the art (see for example P. Wuts and T. Greene, 2007, Protective Groups in Organic Synthesis, Chapter 7, J.
• carbamates such as methyl and ethyl carbamate, FMOC, substituted ethyl carbamates, carbamates cleaved by l,6-P-elimination (also termed "self immolative"), ureas, amides, peptides, alkyl and aryl derivatives.
• Suitable amino- protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC),
• leaving group refers to an group of charged or uncharged moiety that departs during a substitution or displacement.
• leaving groups include, but not limited to, halogens, esters, alkoxy, hydroxyl, tosylates, triflates, mesylates, nitriles, azide, carbamate, disulfides, thioesters, thioethers and diazonium compounds.
• crosslinking agents refers to modifying agents that possess two reactive groups; one of which is capable of reacting with a cell binding agent while the other one reacts with the cytotoxic compound to link the two moieties together. Such bifunctional
• crosslinkers are well known in the art (see, for example, Isalm and Dent in
• bifunctional crosslinking agents that enable linkage via a thioether bond include N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxylate (SMCC) to introduce maleimido groups, or with N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB) to introduce iodoacetyl groups.
• SMCC N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxylate
• SIAB N-succinimidyl-4-(iodoacetyl)-aminobenzoate
• bifunctional crosslinking agents that introduce maleimido groups or haloacetyl groups on to a cell binding agent are well known in the art (see US Patent Applications 2008/0050310, 20050169933, available from Pierce Biotechnology Inc. P.O. Box 117, Rockland, IL 61105, USA) and include, but not limited to, bis-maleimidopolyethyleneglycol (BMPEO), BM(PEO) 2 , BM(PEO) 3 , N-( -maleimidopropyloxy)succinimide ester (BMPS), ⁇ -maleimidobutyric acid N- succinimidyl ester (GMBS), ⁇ -maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5-maleimidovaleric acid NHS, HBVS, N-succinimidyl-4-(N- maleimidomethyl)-cyclohexane-l-carboxy-(6-amidocaproate), which is
• Heterobifunctional crosslinking agents are bifunctional crosslinking agents having two different reactive groups. Heterobifunctional crosslinking agents containing both an amine-reactive N-hydroxysuccinimide group (NHS group) and a carbonyl- reactive hydrazine group can also be used to link the cytotoxic compounds described herein with a cell-binding agent (e.g. , antibody). Examples of such commercially available heterobifunctional crosslinking agents include succinimidyl 6- hydrazinonicotinamide acetone hydrazone (SANH), succinimidyl 4- hydrazidoterephthalate hydrochloride (SHTH) and succinimidyl hydrazinium nicotinate hydrochloride (SHNH).
• SSH succinimidyl 6- hydrazinonicotinamide acetone hydrazone
• SHTH succinimidyl 4- hydrazidoterephthalate hydrochloride
• SHNH succinimidyl hydrazinium nicot
• Conjugates bearing an acid-labile linkage can also be prepared using a hydrazine-bearing benzodiazepine derivative of the present invention.
• bifunctional crosslinking agents include succinimidyl-p-formyl benzoate (SFB) and succinimidyl-p-formylphenoxyacetate (SFPA).
• Bifunctional crosslinking agents that enable the linkage of cell binding agent with cytotoxic compounds via disulfide bonds are known in the art and include N- succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl-4-(2- pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)2-sulfo butanoate (sulfo-SPDB) to introduce dithiopyridyl groups.
• SPDP N- succinimidyl-3-(2-pyridyldithio)propionate
• SPP N-succinimidyl-4-(2- pyridyldithio)pentanoate
• SPDB N-succinimidyl-4-
• crosslinking agents such as 2-iminothiolane, homocysteine thiolactone or S-acetylsuccinic anhydride that introduce thiol groups can also be used.
• a “linker,” “linker moiety,” or “linking group” as defined herein refers to a moiety that connects two groups, such as a cell binding agent and a cytotoxic compound, together. Typically, the linker is substantially inert under conditions for which the two groups it is connecting are linked.
• a bifunctional crosslinking agent may comprise two reactive groups, one at each ends of a linker moiety, such that one reactive group can be first reacted with the cytotoxic compound to provide a compound bearing the linker moiety and a second reactive group, which can then react with a cell binding agent.
• one end of the bifunctional crosslinking agent can be first reacted with the cell binding agent to provide a cell binding agent bearing a linker moiety and a second reactive group, which can then react with a cytotoxic compound.
• the linking moiety may contain a chemical bond that allows for the release of the cytotoxic moiety at a particular site.
• Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, peptidase labile bonds and esterase labile bonds (see for example US Patents 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073). Preferred are disulfide bonds, thioether and peptidase labile bonds.
• Other linkers that can be used in the present invention include non-cleavable linkers, such as those described in are described in detail in U.S. publication number 20050169933, or charged linkers or hydrophilic linkers and are described in US 2009/0274713, US
• the linking group with a reactive group attached at one end is selected from the following:
• n, p, q, m', n' , t' are integer from 1 to 10, or are optionally 0;
• t, m", n", and p are 0 or 1;
• Y" is absent or is selected from O, S, S-S or NR 32 , wherein R 32 has the same definition as given above for R; or
• X" is selected from a maleimido group, a haloacetyl group or SR 37 , wherein R 37 has the same definition as above;
• A" is an amino acid selected from glycine, alanine, leucine, valine, lysine, citrulline and glutamate or a polypeptide containing between 2 to 20 amino acid units;
• R20, R21, R22, R23, R24, R25, R26, and R 2 7 are the same or different, and are -H or a linear or branched alkyl having from 1 to 5 carbon atoms;
• R 2 9 and R30 are the same or different, and are -H or alkyl from 1 to 5 carbon atoms;
• R33 is -H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 12 carbon atoms, a polyethylene glycol unit R-(OCH 2 CH 2 ) n -, or R33 is -COR34, -CSR3 4> - SOR 34 , or -S0 2 R3 4 , wherein R3 4 is H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 20 carbon atoms or, a polyethylene glycol unit -(OCH 2 CH 2 ) n ; and
• R 4 o and R 41 is optionally a negatively or positively charged functional group and the other is H or alkyl, alkenyl, alkynyl having 1 to 4 carbon atoms.
• linking groups may be present in any of the compounds, drug- linker compounds, or conjugates of the invention, including replacing the linking groups of any of the formulas described herein.
• amino acid also refers to the corresponding residue when one hydrogen atom is removed from the amine and/or carboxy end of the amino acid, such as -NH- CiR ⁇ R ⁇ -C ⁇ C O-.
• the term "cation" refers to an ion with positive charge.
• the cation can be monovalent (e.g. , Na + , K + , etc.), bi-valent (e.g. , Ca 2+ , Mg 2+ , etc.) or multi-valent (e.g. , Al 3+ etc.).
• the cation is monovalent.
• terapéuticaally effective amount means that amount of active compound or conjugate that elicits the desired biological response in a subject. Such response includes alleviation of the symptoms of the disease or disorder being treated, prevention, inhibition or a delay in the recurrence of symptom of the disease or of the disease itself, an increase in the longevity of the subject compared with the absence of the treatment, or prevention, inhibition or delay in the progression of symptom of the disease or of the disease itself. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. Toxicity and therapeutic efficacy of compound I can be determined by standard pharmaceutical procedures in cell cultures and in experimental animals.
• the effective amount of compound or conjugate of the present invention or other therapeutic agent to be administered to a subject will depend on the stage, category and status of the multiple myeloma and characteristics of the subject, such as general health, age, sex, body weight and drug tolerance.
• the effective amount of compound or conjugate of the present invention or other therapeutic agent to be administered will also depend on administration route and dosage form. Dosage amount and interval can be adjusted individually to provide plasma levels of the active compound that are sufficient to maintain desired therapeutic effects.
• the present invention is directed to cytotoxic compounds described herein (e.g. , compounds of formulas (I), (II), (III), and (IV)).
• the cytotoxic compounds of the present invention do not include any compounds described in US 2010/0203007 (the entire teaching of which is incorporated herein by reference), such as those specifically disclaimed in the proviso below.
• the invention provides a cytotoxic compound comprising a linking group with a reactive group bonded thereto capable of covalently linking the cytotoxic compound to a cell binding agent (CBA), wherein said cytotoxic compound is re resented by any one of the following formulas (I), (II), (III) or (IV):
• Y is -H or a leaving group selected from -OR, -OCOR' , -OCOOR' , - OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g.
• M is -H or Na + .
• Y is selected from -SO 3 M, -OH, -OMe, -OEt or -NHOH. More preferably, Y is -SO 3 M or - OH; or,
• Y is a sulfite (HS0 3 , HS0 2 or a salt of HS0 3 " , S0 3 2 ⁇ or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 O 5 or a salt of S 2 O 5 " formed with a cation), mono-, di-, tri-, and tetra- thiophosphate (PO 3 SH 3 , P0 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 or a salt of PO 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate ester (R ⁇ PSfOR 1 ), R ; S-, R ; SO, ⁇ 0 2 , R ; S0 3 , thiosulfate (HS 2 0 3 or a salt of
• R for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• R' and R" are the same or different, and are independently selected from -H, -OH, -OR, -NHR, -NR 2 , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , and an optionally substituted 3- tol8-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
• R c is -H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms, or the linking group with the reactive group bonded thereto; n is an integer from 1 to 24;
• X' is selected from the group consisting of -H, -OH, an amine-protecting group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms (e.g.
• X' is -H, - OH, -Me or the linking group with the reactive group bonded thereto. More preferably, X' is -H;
• Y' is selected from the group consisting of -H, an oxo group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18- membered heterocyclic ring having 1 to 6 heteroatoms.
• Y' is selected from -H or oxo. More preferably, Y' is -H;
• one of R 2 , R , R 2 ' and R ' is the linking group with the reactive group bonded thereto and the rest are -H;
• R 6 is -H, -R, -OR, -SR, -NR'R", -N0 2 , halogen, the linking group with the reactive group bonded thereto, -OR c or -SR C , wherein R c is -H, a linear or branched alkyl having 1 to 4 carbon atoms.
• R 6 is -OMe or -SMe. Even more preferably, R 6 is -OMe;
• Z and Z' are independently selected from -(CH 2 ) n -, -(CH 2 ) n -CR 7 R8- (CH 2 ) na -, -(CH 2 V-NR 9 -(CH 2 ) na -, -(CH 2 ) n -0-(CH 2 ) na - and -(CH 2 ) n -S-(CH 2 ) na -; n' and na' are same or different, and are selected from 0, 1, 2 and 3;
• R 7 and R 8 are the same or different, and are each independently selected from -H, -OH, -SH, -COOH, -NHR', a polyethylene glycol unit -(OCH 2 CH 2 ) n -, an amino acid, a peptide unit bearing 2 to 6 amino acids, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms;
• R 9 is independently selected from -H, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH 2 CH 2 )n-;
• a and A' are the same or different, and are selected from -O- and -S-. More preferably, A and A' are -0-;
• R5 for each occurrence is independently -H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
• D and D' are the same or different, and are independently absent or selected from the group consisting of an amino acid, a peptide bearing 2 to 6 amino acids, and a polyethylene glycol unit (-OCH 2 CH 2 ) n -, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, wherein the alkyl, alkenyl and alkynyl are optionally substituted with one or more (e.g. , 2, 3, 4, 5, 6 or more) substituents independently selected from the group consisting of halogen, -OR, -NR'COR", -SR and -COR' ;
• D and D' are the same or different, and are independently selected from linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms. More preferably, D and D' are linear or branched alkyl bearing 1 to 4 carbon atoms. Still more preferably, D and D' are the same or different, and are selected from a linear alkyl having 1 to 4 carbon atoms;
• L is absent, the linking group with the reactive group bonded thereto, a polyethylene glycol unit (-OCH 2 CH 2 ) n -, a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms (e.g.
• a phenyl group a 3- to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P, wherein the alkyl or alkenyl is optionally substituted with the linking group with the reactive group bonded thereto; phenyl or heterocyclic or heteroaryl ring can be optionally substituted, wherein the substituent can be the linking group with the reactive group bonded thereto.
• X is not the linking group with the reactive group bonded thereto.
• the cytotoxic compounds of the present invention are not any one of the following compounds:
• Y is -H or a leaving group selected from -OR, -OCOR' , -OCOOR' , -OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5 or 6-membered nitrogen-containing heterocycle (e.g.
• Y is Sodium Bisulfite adduct, Sodium Hydrosulfite adduct, or Sodium Metabisulfite adduct.
• Y is not -H.
• L is absent, or is selected from an optionally substituted phenyl group and an optionally substituted pyridyl group, wherein the phenyl and the pyridyl group bears the linking group with the reactive group bonded thereto, or L is an amine group bearing the linking group with the reactive group bonded thereto (i.e., - N(linking group)-), or L is a linear, branched or cyclic alkyl or alkenyl having from 1 to 6 carbon atoms and bearing the linking group with the reactive group bonded thereto.
• Y is -H
• R 3 is optionally a linking group and the other is -H;
• R 6 is -OMe
• Z and Z' are -CH 2 -;
• X' is -H
• Y' is -H
• a and A' are -0-; and the remainder of the variables are as described in the first specific embodiment.
• cytotoxic dimers of formula (I), (II), (III) and (IV) are represented by the following formulas:
• Y is selected from -H, -OR, -OCOR', -SR, -NR'R", -S0 3 M, -S0 2 M, or - OS0 3 M, wherein M is -H or a cation such as Na + . K + .
• Y is selected from -OH, -OMe, -OEt, -NHOH or -S0 3 M. Even more preferably, Y is -OH or - S0 3 M, preferably M is -H or Na + ;
• R is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group -(CH 2 CH 2 0) n -R c , wherein n is an integer from 1 to 24 and R c is a linear or branched alkyl having 1 to 4 carbon atoms;
• R' and R" are the same or different, and are selected from -H, -OH, -OR, -NRR g , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted aryl having from 6 to 18 carbon atoms, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group -(CH 2 CH 2 0) n -R c , wherein n is an integer from 1 to 24, preferably n is 2, 4 or 8; and R g is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group - (CH 2 CH 2 0) n -R c ;
• X' is selected from the group consisting of -H, -OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, phenyl, and an amine-protecting group.
• X' is -H, -OH or -Me. More preferably, X' is -H;
• Y' is selected from the group consisting of -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms.
• Y' is selected from -H or -Me. More preferably Y' is -H;
• P 6 is -OR c or -SR C , wherein R c is a linear or branched alkyl having 1 to 4 carbon atoms.
• R 6 is -OMe or -SMe. Even more preferably, R 6 is - OMe;
• a and A' are selected from -O- and -S-.
• a and A' are -0-;
• L' is the linking group with the reactive group bonded thereto.
• one of L', L" or L'" is the linking group with the reactive group bonded thereto, while the others are -H.
• L' is the linking group with the reactive group bonded thereto, and L' ' and L' ' ' are -H;
• G is selected from -CH- or -N-; and the remainder of the variables are as described in the first specific embodiment.
• X is not the linking group with the reactive group bonded thereto.
• the double line— between N and C represents a single bond, Y is not -H.
• a and A' are both -0-, R 6 is -OMe, and G is -CH-.
• L' is represented by the formula:
• R x and R y are the same or different, and are each independently absent or an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, an aryl bearing 6 to 10 carbon atoms or a 3- to 8- membered hetereocyclic ring bearing 1 to 3 heteroatoms selected from O, N or S;
• R e and R e are the same or different, and are selected from -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or - (CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g.
• R 101 and R 102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms.
• R 101 and R 102 are each independently a linear or branched alkyl having 1 to 6 carbon atoms;
• n is an integer from 1 to 24;
• J comprises the reactive group bonded thereto, and is selected from a maleimide, a haloacetamido, -SH, -SSR d , -CH 2 SH, -CH(Me)SH, -C(Me) 2 SH, - NHR cl , -CH 2 NHR cl , -NR cl NH 2 , -COOH, and -COE, wherein -COE represents a reactive ester selected from, but not limited to, N-hydroxysuccinimde ester, N- hydroxy sulfosuccinimide ester, nitrophenyl (e.g. , 2 or 4-nitrophenyl) ester, dinitrophenyl (e.g.
• R cl is - H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms
• R d is selected from phenyl, nitrophenyl (e.g. , 2 or 4-nitrophenyl), dinitrophenyl (e.g. , 2 or 4-nitrophenyl), carboxynitrophenyl (e.g. , 3-carboxy-4- nitrophenyl), pyridyl or nitropyridyl (e.g. , 4-nitropyridyl).
• J is -SH, -SSR d , a maleimide, or a N- hydroxysuccinimide ester.
• R e is -H or -Me; R e is a linear or branched alkyl having 1 to 6 carbon atoms or -(CH 2 -CH 2 -0) n -R k ; n is an integer from 2 to 8; preferably R k is - H, -Me or -CH 2 CH 2 -NMe 2 , and the remainder of the variables are as described above in the fourth specific embodiment.
• V is an amino acid or a peptide having 2 to 8 amino acids. In certain embodiments, V is valine-citrulline, gly-gly-gly, or ala-leu-ala-leu.
• R e is H, a linear or branched alkyl having 1 to 4 carbon atoms, or -(CH 2 - CH 2 -0) n -R k ;
• R x is a linear or branched alkyl having 1 to 6 carbon atoms
• R y is absent or a linear or branched alkyl having 1 to 4 carbon atoms; and J is -SH, -SSR d or -COE (preferably, N-hydroxysuccinimide ester). The remainder of the variables is as described in the fourth specific embodiment.
• R e is H, Me, or -(CH 2 -CH 2 -0) n -Me;
• n is an integer from 2 to 6;
• R x is linear or branched alkyl bearing 1 to 6 carbon atoms
• V and R y are absent;
• J is -COE, preferably N-hydroxysuccinimide ester.
• the remainder of the variables is as described in the fourth specific embodiment.
• L' is represented by the following formula:
• Rr s R 2 ", and R 3 " are each independently -H or a linear or branched alkyl bearing 1 to 4 carbon atoms, preferably -Me;
• R 4 " is -H, a linear or branched alkyl bearing 1 to 4 carbon atoms
• M + is a pharmaceutically acceptable cation
• a is an integers from 0-5 (e.g. , from 0 to 2, 3, 4, or 5), and b is an integer from 0-6 (e.g. , from 0 to 3, 4, 5, or 6); and,
• Cy is an optionally substituted 5-membered heterocyclic ring bearing an N heteroatom, preferably Cy is
• W is -N(R 6 )-.
• R e is -(CH 2 -CH 2 -0) 2-6 - R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms.
• V is -S- or -SS-.
• L' is represented by the following formula:
• the compound is any of the following:
• Y is -H or -SO 3 M
• M is -H or a pharmaceutically acceptable cation.
• Y is -SO 3 M.
• L' is represented by the following formula:
• the compound is any one of the following:
• Y is -H or -SO 3 M
• M is -H or a pharmaceutically acceptable cation.
• Y is -SO 3 M.
• cytotoxic dimers of formula (I), (II), (III) and (IV) are represented by the following formulas:
• R x is absent or selected from a linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
• R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g. , -NHR 101 ) or tertiary amino (-NR 101 R 102 ) group or a 5- or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R 101
• R 101 and R 102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms.
• R 101 and R 102 are each independently a linear or branched alkyl having 1 to 6 carbon atoms;
• Z s is -H, -SR m ;
• R m is R d or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms bearing a reactive ester, selected from N- hydroxysuccinimide esters, N-hydroxyphtalimide esters, N-hydroxy sulfo- succinimide esters, para-nitrophenyl esters, dinitrophenyl esters,
• R d is selected from phenyl, nitrophenyl, dinitrophenyl,
• n is an integer from 1 to 24; and the remainder of the variables are as described above in the third specific embodiment.
• R k is -H or -Me, and n is an integer from 2 to 8.
• R x is a linear or branched alkyl having 1 to 6 carbon atoms; and the remainder of the variables is as described above in the thrid, fourth, and/or the fifth specific embodiment.
• cytotoxic dimers of formula (I), (II), (III) and (IV) are represented by the following formulas:
• Y is selected from -H, -OR, -OCOR', -SR, -NR'R,” -S0 3 M, -S0 2 M or - OS0 3 M (e.g. , Y is -OR, -OCOR' , -SR, -NR'R,” -S0 3 M, -S0 2 M or -OS0 3 M), wherein M is -H or a cation such as Na + or K + ;
• R is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group -(CH 2 CH 2 0) n -R c , wherein n is an integer from 1 to 24, and R c is a linear or branched alkyl having 1 to 4 carbon atoms;
• R' and R" are the same or different, and are selected from -H, -OH, -OR, -NRR g , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted aryl having from 6 to 18 carbon atoms, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group -(CH 2 CH 2 0) n -R c , wherein n is an integer from 1 to 24, preferably n is 2, 4 or 8; and R g is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group - (CH 2 CH 2 0) n -R c ;
• X' is selected from the group consisting of -H, -OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, phenyl, and an amine-protecting group;
• Y' is selected from the group consisting of -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms;
• a and A' are selected from -O- and -S-;
• R x is absent or selected from a linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
• R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g. , -NHR 101 ) or tertiary amino (-NR 101 R 102 ) group or a 5 or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R 101
• R are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms;
• G is selected from -CH- or -N-;
• Z s -H or is selected from any one of the following formulas:
• q is an integer from 1 to 5;
• n is an integer from 2 to 6;
• M is -H or a cation, such as Na + or K + .
• Z s is represented by any one of the following formulas:
• W is -N(R 6 )-.
• R e is -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms.
• R k is -H or -Me
• n is 4, and q is 2.
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• R x may be -(CH 2 ) p -(CR f R g )-, wherein R f and R g are each independently selected from H or a linear or branched alkyl having 1 to 4 carbon atoms; and p is 0, 1, 2 or 3.
• R f and R g are the same or different, and are selected from -H and -Me; and p is 1.
• the double line— between N and C represents a single bond or a double bond, provided that when it is a double bond X is absent and Y is -H, and when it is a single bond, X is -H; Y is -H, -OH or -S0 3 M;
• M is -H or a pharmaceutically acceptable cation (e.g. , Na + ); X' and Y' are both -H;
• a and A' are both -0-;
• R 6 is -OMe
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• Y is -OH or -S0 3 M.
• R x is absent or selected from a linear, branched or cyclic alkyl having 1 to 6 carbon atoms;
• R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a primary, secondary or tertiary amino group or a 5- or 6-membered Nitrogen containing heterocycle, such as piperidine or morpholine;
• n is an integer from 1 to 24; and the remainder of the variables are as described above in the ninth specific embodiment.
• R k is -H or -Me
• n is an integer from 2 to 8.
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• R x is -(CH 2 ) p -(CR f R g )-, wherein R f and R g are each independently selected from H or a linear or branched alkyl having 1 to 4 carbon atoms; p is 0, 1, 2 or 3. More preferably, R f and R g are the same or different, and are selected from -H and - Me; and p is 1.
• the linker is represented by any one of the formula selected from formulas (al), (a4), (a5), (alO) and (al l) shown above; and the remainder of the variables are as described above in the tenth specific embodiment.
• M is -H or Na + ;
• X' and Y' are both -H;
• a and A' are both -0-;
• R 6 is -OMe
• R x is a linear or branched alkyl having 1 to 6 carbon atoms; and the remainder of the variables is as described above in the thrid, fourth, or the fifth specific embodiment.
• R x is -(CH 2 ) p -(CR f R g )-, wherein R f and R g are each independently selected from H or a linear or branched alkyl having 1 to 4 carbon atoms; p is 0, 1, 2 or 3. More preferably, R f and R g are the same or different, and are selected from -H and - Me; and p is 1.
• X is - H
• the linking group with the reactive group bonded thereto or an amine protecting group (e.g., X is -H or or an amine protecting group)
• Y is selected from -H, -OR, - OCOR', -SR, -NR'R," an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, -S0 3 M, -S0 2 M and a sulfate -OS0 3 M (e.g.
• Y is -OR, -OCOR' , -SR, - NR'R," an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, - S0 3 M, -S0 2 M and a sulfate -OS0 3 M).
• Y is selected from -H, -S0 3 M, -OH, -OMe, -OEt or - NHOH (e.g. , Y is -S0 3 M, -OH, -OMe, -OEt or -NHOH).
• Y is -H, -S0 3 M or -OH (e.g. , Y is -S0 3 M or -OH).
• M is -H, Na + or K + .
• Z and Z' when present, are -CH 2 .
• X' is selected from the group consisting of -H, -OH, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, phenyl, the linking group with the reactive group bounded thereto, and an amine-protecting group.
• X' is -H, -OH, -Me or the linking group with the reactive group bounded thereto.
• X' is -H.
• Y' is selected from the group consisting of -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms.
• Y' is -H or oxo.
• Y' is -H.
• a and A' may be same or different and selected from -O- and -S-.
• both A and A' are -0-.
• D and D' when present, are the same or different, and are independently selected from a polyethylene glycol unit (-OCE ⁇ CEy n , wherein n is an integer from 1 to 24, an amino acid, a peptide bearing 2 to 6 amino acids, or a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, wherein the alkyl, alkenyl and alkynyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR, -NR'COR" , -SR and -COR' .
• D and D' are linear or branched alkyl bearing 1 to 4 carbon atoms.
• the cytotoxic compound of the present invention as described in the first, third, and ninth embodiment is represented by the following:
• Y is -H
• R 3 is optionally the linking group with the reactive group bounded thereto and the other is -H;
• R 6 is -OMe
• Z and Z' are -CH 2 ;
• X' is -H
• Y' is -H
• a and A' are -0-.
• the cytotoxic compound of the present invention is:
• compound 29b can used in methods of the present invention described herein.
• compound 29b can be used for treating a proliferative disorder, such as cancer.
• compound 29b can be used for screening cell lines to identify cell lines that are sensitive to benzodiazepine compounds, such as
• the cytotoxic compounds described above comprise a linking group with a reactive group bonded thereto, which compounds may result from reacting a
• bifunctional crosslinking reagent with "linker-less” compounds to form the so-called drug-linker compounds.
• drug compounds that are otherwise identical to the drug-linker compounds, but without the linker moiety are also encompassed by the present invention.
• the invention provides a cytotoxic compound without linking group, but may be capable of reacting with a bifunctional crosslinking agent to form a compound of the invention, such as any one of the 1 st to the 12 th specific embodiments described above; or to form a cell-binding agent conjugate of the invention (such as those described below).
• a linkerless cytotoxic compound of the invention includes compound 29b of the 13 th specific embodiment above.
• the linkerless cytotoxic compounds of the invention are represented by any one of the following formulas ( ⁇ ), ( ⁇ ), ( ⁇ ) or (IV):
• Y is -H or a leaving group selected from -OR, -OCOR' , -OCOOR' , - OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g.
• M is -H or Na + .
• Y is selected from -SO 3 M, -OH, -OMe, -OEt or -NHOH. More preferably, Y is -SO 3 M or - OH; or,
• Y is a sulfite (HS0 3 , HS0 2 or a salt of HS0 3 " , S0 3 2" or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 0 5 or a salt of S 2 0 5 " formed with a cation), mono-, di-, tri-, and tetra- thiophosphate (PO 3 SH 3 , P0 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 or a salt of PO 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate ester (R ⁇ PSfOR 1 ), R ; S-, R ; SO, R ; S0 2 , R ⁇ Os, thiosulfate (HS 2 0 3 or a salt of
• R for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• R' and R" are the same or different, and are independently selected from -H, -OH, -OR, -NHR, -NR 2 , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , and an optionally substituted 3- tol8-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
• R c is -H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms;
• n is an integer from 1 to 24;
• X' is selected from the group consisting of -H, -OH, an amine-protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms (e.g. , phenyl), an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P.
• X' is -H, -OH, or -Me. More preferably, X' is -H;
• Y' is selected from the group consisting of -H, an oxo group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms.
• Y' is selected from -H or oxo. More preferably, Y' is - H;
• R 6 is -H, -R, -OR, -SR, -NR'R", -N0 2 , halogen, -OR c or -SR C , wherein R c is -H, a linear or branched alkyl having 1 to 4 carbon atoms.
• R 6 is -OMe or -SMe. Even more preferably, R 6 is -OMe;
• Z and Z' are independently selected from -(CH 2 ) n '-, -(CH 2 ) n --CR 7 R8- (CH 2 ) na -, -(CH 2 V-NR 9 -(CH 2 ) na -, -(CH 2 ) n -0-(CH 2 ) na - and -(CH 2 ) n -S-(CH 2 ) na -; n' and na' are same or different, and are selected from 0, 1, 2 and 3;
• R 7 and Rg are the same or different, and are each independently selected from -H, -OH, -SH, -COOH, -NHR', a polyethylene glycol unit -(OCH 2 CH 2 ) n -, an amino acid, a peptide unit bearing 2 to 6 amino acids, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms;
• R9 is independently selected from -H, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH 2 CH 2 ) n -;
• a and A' are the same or different, and are selected from -O- and -S-. More preferably, A and A' are -0-;
• R5 for each occurrence is independently -H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
• L', L", and L" ' are the same or different, and are independently selected from -H, halogen, an optionally substituted linear, branched or cyclic alkyl, haloalkyl, alkoxy, haloalkoxy, -N0 2 , or -CN;
• G is selected from -CH- or -N-.
• Y is selected from -OR, -OCOR', -SR, -NR'R", - S0 3 M, -S0 2 M, or -OS0 3 M, wherein M is -H or a cation such as Na + . K + .
• Y is selected from -H, -OH, -OMe, -OEt, -NHOH or -S0 3 M (e.g. , Y is -OH, -OMe, -OEt, - NHOH or -SO 3 M).
• Y is -H, -OH or -S0 3 M (e.g. , Y is -OH or - S0 3 M), preferably M is -H or Na + .
• the bifunctional crosslinking agents can be any bifunctional linker known in the art.
• the bifunctional linkers can be used for making the drug-linker compounds are those that form disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, peptidase labile bonds and esterase labile bonds with the cytotoxic compounds (see for example, US Patent 5,208,020; 5,475,092; 6,441,163; 6,716,821 ; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073, all of which are incorporated herein by reference).
• the bifunctional crosslinking agents are those that form disulfide bonds, thioether and peptidase labile bonds with the cytotoxic compounds.
• Other bifunctional crosslinking agents that can be used in the present invention include non-cleavable linkers, such as those described in U.S. publication number US 2005/0169933, or charged linkers or hydrophilic linkers and are described in US 2009/0274713, US 2010/01293140 and WO 2009/134976, each of which is expressly incorporated herein by reference.
• the bifunctional crosslinking agents that can be used for making the (drug-linker) compounds of the present invention also include those described in Thermo Scientific Pierce Crosslinking Technical Handbook, the entire teaching of which is incorporated herein by reference.
• FIGS. 1-11 Representative processes for preparing the cytotoxic dimer compounds of the present invention are shown in FIGS. 1-11.
• the dimers were prepared by reacting a monomer with linker compounds which possess two leaving groups such as halogen, triflate, mesylate, or tosylate such as that described for the synthesis of lc in FIG. 1.
• linker compounds which possess two leaving groups such as halogen, triflate, mesylate, or tosylate such as that described for the synthesis of lc in FIG. 1.
• FIG. 3 describes a dimer possessing a short polyethylene glycol moiety and an amide disulfide which was reduced to thiol 4c and converted to a reactive ester.
• FIG. 5 describes the synthesis of pyridyl disulfide containing linker 5e which was converted to the mono-imine thiol 5i of the present invention before being converted to a reactive ester.
• representative dimers which possess linkers that can react with cell binding agents are prepared by converting the methyl esters to the corresponding reactive esters of a leaving group such as, but not limited to, N-hydroxysuccinimide esters, N- hydroxyphthalimide esters, N-hydroxy sulfo-succinimide esters, para-nitrophenyl esters, pentafluorophenyl esters are shown in FIGS. 6, 9, and 11.
• FIGS. 1 and 12-19 Representative processes for preparing the cytotoxic dimer compounds of the present invention suitable for one-step conjugation with a cell binding agent are shown in FIGS. 1 and 12-19.
• a dimer containing a thiol moiety is reacted with a bifunctional crosslinking reagent possessing a reactive group such as, but not limited to, a thiopyridyl, a maleimide, iodide, bromide, or tosylate on one side and a reactive substituent suitable for reaction with a cell binding agent such as, but not limited to, N-hydroxysuccinimide esters, N-hydroxyphtalimide esters, N-hydroxy sulfo- succinimide esters, paranitrophenyl esters, pentafluorophenyl esters.
• a bifunctional crosslinking reagent possessing a reactive group such as, but not limited to, a thiopyridyl, a maleimide, i
• FIGS. 20-21 Alternative synthetic processes for preparing representative cytotoxic dimer compounds of the present invention are shown in FIGS. 20-21.
• the synthesis of the mono reduced dimer i.e. , having one imine group
• the synthesis of the mono reduced dimer is accomplished by a two step coupling method, in which a reduced form of monomer is either initially coupled to the linker followed by coupling with the IBD monomer or the dimer is prepared using a mixture of both reduced monomer and the IBD monomer in the coupling with the reactive linker.
• the di-reduced dimer is potentially a byproduct of the second synthetic pathway previously described, a more direct route is shown in FIG. 21 in which the reduced monomer is coupled to both with the linker directly.
• Cell-binding agents may be of any kind presently known, or that become known and includes peptides and non-pep tides. Generally, these can be antibodies (especially monoclonal antibodies), lymphokines, hormones, growth factors, vitamins (such as folate etc. , which may bind to a cell surface receptor thereof, e.g. , a folate receptor), nutrient-transport molecules (such as transferrin), or any other cell-binding molecule or substance.
• the cell-binding agents are proteins or polypeptides, or compounds comprising proteins or polypeptides.
• polypeptides comprise one or more Lys residues with side chain - ⁇ 2 groups.
• the proteins or polypeptides comprise one or more Cys residues.
• the side chain -SH groups of the Cys residues may be intact, or may be in a disulfide bond that can be reduced.
• reduction of the disulfide bond(s) does not significantly negatively impact the cell-binding function of the proteins or polypeptides (e.g. , in the case of antibody or antigen-binding portion thereof, reduction of the disulfide bonds does not substantially increase the dissociation of light chains / heavy chains).
• the Lys side chain -NH 2 groups and/or the Cys side chain -SH groups may be covalently linked to the linkers, which are in turn linked to the dimer compounds of the invention, thus conjugating the cell-binding agents to the dimer compounds of the invention.
• Each protein-based cell-binding agents may contain multiple Lys side chain - NH 2 groups and/or the Cys side chain -SH groups available for linking the compounds of the invention through the bifunctional crosslinkers.
• cell-binding agents that can be used include:
• interferons e.g. cc, ⁇ , ⁇
• lymphokines such as IL-2, IL-3, IL-4, IL-6;
• hormones such as insulin, TRH (thyrotropin releasing hormone), MSH
• melanocyte-stimulating hormone steroid hormones, such as androgens and estrogens
• growth factors and colony- stimulating factors such as EGF, TGF-alpha, FGF, VEGF, G-CSF, M-CSF and GM-CSF (Burgess, Immunology Today 5:155-158 (1984)); transferrin (O'Keefe et al. J. Biol. Chem. 260:932-937 (1985));
• vitamins such as folate
• Protein scaffolds based on a consensus sequence of fibronectin type III (FN3) repeats also known as Centyrins; See U.S. Patent Publication 2010/0255056, incorporated herein by reference;
• Fibronectin domain scaffold proteins (Adnectins: US Patent Application Nos. 20070082365; 20080139791, incorporated herein by reference).
• Monoclonal antibody techniques allow for the production of extremely specific cell-binding agents in the form of specific monoclonal antibodies.
• Particularly well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
• Sensitized human cells can also be used.
• Another method of creating monoclonal antibodies is the use of phage libraries of scFv (single chain variable region), specifically human scFv (see e.g., Griffiths et al, U.S. Patent Nos.
• the monoclonal antibody MY9 is a murine IgGl antibody that binds specifically to the CD33 Antigen ⁇ J.D. Griffin et al 8 Leukemia Res., 521 (1984) ⁇ and can be used if the target cells express CD33 as in the disease of acute myelogenous leukemia (AML).
• the cell-binding agent may be any compound that can bind a cell, either in a specific or non-specific manner. Generally, these can be antibodies (especially monoclonal antibodies and antibody fragments), interferons, lymphokines, hormones, growth factors, vitamins, nutrient-transport molecules (such as transferrin), or any other cell-binding molecule or substance.
• the cell-binding agent binds to an antigen that is a polypeptide and may be a transmembrane molecule (e.g. receptor) or a ligand such as a growth factor.
• antigens include molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha- 1 -antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor vmc, factor ⁇ , tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin;
• hemopoietic growth factor tumor necrosis factor-alpha and -beta; enkephalinase;
• RANTES regulated on activation normally T-cell expressed and secreted
• human macrophage inflammatory protein MIP-1 -alpha
• a serum albumin such as human serum albumin
• Muellerian-inhibiting substance such as beta- lactamase; DNase; IgE
• a cytotoxic T-lymphocyte associated antigen CLA
• CTLA cytotoxic T-lymphocyte associated antigen
• VEGF vascular endothelial growth factor
• receptors for hormones or growth factors protein A or D
• rheumatoid factors a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT4, NT-5, or NT-6), or a nerve growth factor such as NGF- ⁇ ; platelet-derived growth factor (PDGF); fibroblast growth factor such as
• erythropoietin erythropoietin
• osteoinductive factors immunotoxins
• a bone morphogenetic protein BMP
• an interferon such as interferon- alpha, -beta, and -gamma
• colony stimulating factors CSFs
• M-CSF e.g. , M-CSF, GM-CSF, and G-CSF
• ILs interleukins
• IL-1 to IL- 10 superoxide dismutase
• T-cell receptors surface membrane proteins
• decay accelerating factor viral antigen such as, for example, a portion of the HIV envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins, such as CDl la, CDl lb, CDl lc, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 or HER4 receptor; endoglin, c-Met, c-kit, 1GF1R, PSGR, NGEP, PSMA, PSCA, LGR5, B7H4, and fragments of any of the above-listed polypeptides.
• GM-CSF which binds to myeloid cells can be used as a cell- binding agent to diseased cells from acute myelogenous leukemia.
• IL-2 which binds to activated T-cells can be used for prevention of transplant graft rejection, for therapy and prevention of graft- versus-host disease, and for treatment of acute T-cell leukemia.
• MSH which binds to melanocytes, can be used for the treatment of melanoma, as can antibodies directed towards melanomas.
• Folic acid can be used to target the folate receptor expressed on ovarian and other tumors.
• Epidermal growth factor can be used to target squamous cancers such as lung and head and neck.
• Somatostatin can be used to target neuroblastomas and other tumor types.
• Cancers of the breast and testes can be successfully targeted with estrogen (or estrogen analogues) or androgen (or androgen analogues) respectively as cell-binding agents.
• the cell-binding agent is humanized monoclonal antibodies.
• the cell-binding agent is huMy9-6, or other related antibodies, which are described in U.S. Pat. Nos. 7,342,110 and 7,557,189 (incorporated herein by reference).
• the cell-binding agent is an anti-folate receptor antibody described in U.S. Provisional Application Nos. 61/307,797, 61/346,595, 61/413,172 and U.S. Application No. 13/033,723 (published as US 2012-0009181 Al). The teachings of all these applications are incorporated herein by reference in its entirety.
• the cell-binding agent may be a monoclonal antibody or antigen-binding portions thereof sharing sequences critical for antigen-binding with an antibody disclosed herein, such as huMy9-6 or its related antibodies described in U.S. Pat. Nos. 7,342,110 and 7,557,189 (incorporated herein by reference).
• These derivative antibodies may have substantially the same or identical (1) light chain and/or heavy chain CDR3 regions; (2) light chain and/or heavy chain CDR1, CDR2, and CDR3 regions; or (3) light chain and/or heavy chain regions, compared to an antibody described herein. Sequences within these regions may contain conservative amino acid subsitutions, including substitutions within the CDR regions.
• the derivative antibodies have a light chain region and/or a heavy chain region that is at least about 90%, 95%, 99% or 100% identical to an antibody described herein.
• These derivative antibodies may have substantially the same binding specificity and/or affinity to the target antigen compared to an antibody described herein.
• the K ⁇ j and/or R values of the derivative antibodies are within 10-fold (either higher or lower), 5-fold (either higher or lower), 3-fold (either higher or lower), or 2-fold (either higher or lower) of an antibody described herein.
• These derivative antibodies may be fully human antibodies, or humanized antibodies, or chimeric antibodies.
• the derivative antibodies may be produced according to any art-recognized methods.
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof that specifically binds a human folate receptor 1, wherein the antibody comprises: (a) a heavy chain CDR1 comprising GYFMN (SEQ ID NO: 1); a heavy chain CDR2 comprising (SEQ ID NO: 2); and a heavy chain CDR3 comprising YDGSRAMDY (SEQ ID NO: 3); and (b) a light chain CDR1 comprising KASQSVSFAGTSLMH (SEQ ID NO: 4); a light chain CDR2 comprising RASNLEA (SEQ ID NO: 5); and a light chain CDR3 comprising QQSREYPYT (SEQ ID NO: 6); wherein Xaa x is selected from K, Q, H, and R; Xaa 2 is selected from Q, H, N, and R; and Xaa 3 is selected from G, E, T, S, A, and V.
• the antibody comprises: (a) a heavy chain C
• the heavy chain CDR2 sequence comprises RIHPYDGDTFYNQKFQG (SEQ ID NO: 7).
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof that specifically binds the human folate receptor 1 comprising the heavy chain having the amino acid sequence of
• the anti-folate antibody is a humanized antibody or antigen binding fragment thereof encoded by the plasmid DNA deposited with the ATCC on April 7, 2010 and having ATCC deposit nos. PTA-10772 and PTA-10773 or 10774.
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof that specifically binds the human folate receptor 1 comprising the light chain having the amino acid sequence of DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRA SNLEAGVPDRFSGSGSKTDFTLNISPVEAEDAATYYCQQSREYPYTFGGGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• DrVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRA SNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof that specifically binds the human folate receptor 1 comprising the heavy chain having the amino acid sequence of SEQ ID NO: 8, and the light chain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.
• the antibody comprises the heavy chain having the amino acid sequence of SEQ ID NO: 8 and the light chain having the amino acid sequence of SEQ ID NO: 10 (hu FOLR1).
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof encoded by the plasmid DNA deposited with the ATCC on April 7, 2010 and having ATCC deposit nos. PTA-10772 and PTA- 10773 or 10774.
• the anti-folate receptor antibody is a humanized antibody or antigen binding fragment thereof comprising a heavy chain variable domain at least about 90%, 95%, 99% or 100% identical to
• the present invention also provides cell-binding agent-drug conjugates comprising a cell-binding agent linked to one or more cytotoxic compounds of the present invention via a variety of linkers, including, but not limited to, disulfide linkers, thioether linkers, amide bonded linkers, peptidase-labile linkers, acid-labile linkers, esterase-labile linkers.
• linkers including, but not limited to, disulfide linkers, thioether linkers, amide bonded linkers, peptidase-labile linkers, acid-labile linkers, esterase-labile linkers.
• Representative conjugates of the invention are antibody / cytotoxic compound, antibody fragment / cytotoxic compound, epidermal growth factor (EGF) / cytotoxic compound, melanocyte stimulating hormone (MSH) / cytotoxic compound, thyroid stimulating hormone (TSH) / cytotoxic compound, somatostatin/cytotoxic compound, folate / cytotoxic compound, estrogen / cytotoxic compound, estrogen analogue / cytotoxic compound, androgen/cytotoxic compound, and androgen analogue / cytotoxic compound.
• a representative folate / cytotoxic compound conjugate is depicted below, with the optional -S0 3 ⁇ Na + adduct on the imine bond of one of the two drug monomers.
• a representative synthesis scheme for this conjugate is shown in Figure 54.
• the present invention provides conjugates comprising an indolinobenzodiazepine dimer compound (e.g. , compounds of formulas (I)-(IV), (IA)-(IVA) and (IB)-(IVB)) and the cell-binding agent linked through a covalent bond.
• the linker can be cleaved at the site of the tumor/unwanted proliferating cells to deliver the cytotoxic agent to its target in a number of ways.
• the linker can be cleaved, for example, by low pH (hydrazone), reductive environment (disulfide), proteolysis (amide/peptide link), or through an enzymatic reaction (esterase/glycosidase).
• cytotoxic conjugates of the invention are antibody / indolinobenzodiazepine dimer compound, antibody fragment /
• indolinobenzodiazepine dimer compound epidermal growth factor (EGF) / indolinobenzodiazepine dimer compound, melanocyte stimulating hormone (MSH) / indolinobenzodiazepine dimer compound, thyroid stimulating hormone (TSH) / indolinobenzodiazepine dimer compound, somatostatin/ indolinobenzodiazepine dimer compound, folate/ indolinobenzodiazepine dimer compound, estrogen /
• indolinobenzodiazepine dimer compound indolinobenzodiazepine dimer compound
• estrogen analogue indolinobenzodiazepine dimer compound
• PSMA prostate specific membrane antigen
• indolinobenzodiazepine dimer compound matriptase inhibitor / indolinobenzodiazepine dimer compound, designed ankyrin repeat proteins (DARPins) /
• indolinobenzodiazepine dimer compound androgen / indolinobenzodiazepine dimer compound, and androgen analogue/ indolinobenzodiazepine dimer compound.
• the invention provides a conjugate comprising: a cytotoxic compound and a cell binding agent (CBA), wherein the cytotoxic compound comprises a linking group which covalently links the cytotoxic compound to the CBA, and wherein the cytotoxic compound is represented by any one of the followin formulas:
• Y is -H or a leaving group selected from -OR, -OCOR', -OCOOR' , - OCONR'R” , -NR'R", -NR'COR", -NR'NR'R” , an optionally substituted 5 or 6-membered nitrogen-containing heterocycle (e.g.
• an amino acid or a peptide represented by -NRCOP'
• P' is an amino acid or a polypeptide containing between 2 to 20 amino acid units, -SR, -SOR', - S0 2 M, -SO 3 M, -OSO 3 M, halogen, cyano and an azido; or,
• Y is a sulfite (HS0 3 , HS0 2 or a salt of HS0 3 " , S0 3 2 ⁇ or HS0 2 " formed with a cation), metabisulfite (H 2 S 2 O 5 or a salt of S 2 O 5 " formed with a cation), mono-, di-, tri-, and tetra- thiophosphate (PO 3 SH 3 , P0 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 or a salt of PO 3 S 3" , P0 2 S 2 3" , POS 3 3” or PS 4 3" formed with a cation), thio phosphate ester (R ⁇ PSfOR 1 ), R ; S-, R ; SO, ⁇ 80 2 , R ⁇ Os, thiosulfate (HS 2 0 3 or a salt of
• M is -H or a cation
• R for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• R' and R' ' are each independently selected from -H, -OH, -OR, -NHR, - NR 2 , -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (CH 2 CH 2 0) n -R c , and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
• R c is -H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms, or the linking group;
• n is an integer from 1 to 24;
• X' is selected from -H, an amine-protecting group, the linking group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH 2 CH 2 0) n -R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
• Y' is selected from -H, an oxo group, the linking group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms;
• R 6 is -H, -R, -OR, -SR, -NR'R", -N0 2 , halogen or the linking group;
• Z and Z' are independently selected from -(CH 2 ) n -, -(CH 2 ) n -CR 7 R8- (CH 2 ) na -, -(CH 2 ) n -NR 9 -(CH 2 ) na -, -(CH 2 ) n ⁇ -0-(CH 2 ) na ⁇ - and -(CH 2 ) n -S-(CH 2 ) na -; n' and na' are the same or different, and are selected from 0, 1, 2 and 3;
• R 7 and R 8 are the same or different, and are each independently selected from -H, -OH, -SH, -COOH, -NHR', a polyethylene glycol unit -(OCH 2 CH 2 ) n -, an amino acid, a peptide unit bearing 2 to 6 amino acids, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms;
• R 9 is independently selected from -H, an optionally substituted linear, branched or cyclic alkyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH 2 CH 2 ) n -;
• R 5 for each occurrence is independently -H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
• D and D' are the same or different, and are independently absent or selected from the group consisting of an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, an amino acid, a peptide bearing 2 to 6 amino acids, and a polyethylene glycol unit (-OCH 2 CH 2 ) n -
• L is absent, the linking group, a polyethylene glycol unit (-OCH 2 CH 2 ) n -, a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3- to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P, wherein the alkyl or alkenyl is optionally substituted with the linking group; phenyl or heterocyclic or heteroaryl ring can be optionally substituted, wherein the substituent can be the linking group.
• a polyethylene glycol unit (-OCH 2 CH 2 ) n - a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3- to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1
• X is not the linking group.
• Y is a leaving group selected from -OR, -OCOR', - OCOOR', -OCONR'R", -NR'R", -NR'COR", -NR'NR'R", an optionally substituted 5 or 6-membered nitrogen-containing heterocycle (e.g.
• an amino acid or a peptide represented by -NRCOP'
• P' is an amino acid or a polypeptide containing between 2 to 20 amino acid units, -SR, -SOR' , -S0 2 M, -SO 3 M, - OSO 3 M, halogen, cyano and an azido.
• the compound is not any one of the following compounds:
• CBA is the cell-binding agent
• r is an integer from 1 to 10
• Y is -H
• M is -H or a pharmaceutically acceptable cation.
• L is absent, or is selected from an optionally substituted phenyl group and an optionally substituted pyridyl group, wherein the phenyl and the pyridyl group bears the linking group, or L is an amine group bearing the linking group (i.e., -N(linking group)-), or L is a linear, branched or cyclic alkyl or alkenyl having from 1 to 6 carbon atoms and bearing the linking group.
• G is selected from -CH- or -N-.
• the remaining groups are as described in the fourteenth specific embodiment above.
• one of L', L", or L'" is the linking group, while the others are -H.
• L' is the linking group
• L" and L" ' are -H.
• a and A' are both -0-, R 6 is -OMe, and G is -CH-.
• L' is represented by the following formula:
• R x and R y are the same or different, and are each independently absent or an optionally substituted linear, branched or cyclic alkyl, alkenyl, or alkynyl having 1 to 10 carbon atoms, an aryl bearing 6 to 10 carbon atoms or a 3- to 8- membered hetereocyclic ring bearing 1 to 3 heteroatoms selected from O, N or S;
• R e and R e are the same or different, and are selected from -H, a linear, branched or cyclic alkyl, alkenyl, or alkynyl having 1 to 10 carbon atoms or - (CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g. , -NHR 101 ) or tertiary amino (-NR 101 R 102 ) group or a 5- or 6-membered nitrogen containing
• R 101 and R 102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms; preferably, R 101 and R 102 are each independently a linear or branched alkyl having 1 to 6 carbon atoms;
• n is an integer from 1 to 24;
• R e is -H or -Me; R e is a linear or branched alkyl having 1 to 6 carbon atoms or -(CH 2 -CH 2 -0) n -R k ; n is an integer from 2 to 8; and R k is -H, -Me or -CH 2 CH 2 -NMe 2 , and the remainder of the variables are as described above in the fifteenth specific embodiment.
• V is an amino acid or a peptide having 2 to 8 amino acids.
• V is valine-citrulline, gly-gly-gly, or ala-leu-ala-leu.
• R e is H, a linear or branched alkyl having 1 to 4 carbon atoms, or -(CH 2 - CH 2 -0) n -R k ;
• R x is a linear or branched alkyl having 1 to 6 carbon atoms
• R e is -H, -Me, or -(CH 2 -CH 2 -0) n -Me;
• n is an integer from 2 to 6;
• R x is linear or branched alkyl bearing 1 to 6 carbon atoms
• V and R y are absent;
• the remaining groups are as defined in the sixteenth specific embodiment.
• L' in the sixteenth specific embodiment is represented by the following formula:
• Rr , R 2 ", and R 3 " are each independently -H or a linear or branched alkyl bearing 1 to 4 carbon atoms, preferably -Me;
• R 4 " is -H, a linear or branched alkyl bearing 1 to 4 carbon atoms
• M + is a pharmaceutically acceptable cation
• a is an integers from 0-5 (e.g. , from 0 to 2, 3, 4, or 5), and b is an integer from 0-6 (e.g. , from 0 to 3, 4, 5, or 6); and,
• Cy is an optionally substituted 5-membered heterocyclic ring bearing an N heteroatom, preferably Cy is
• W is -N(R 6 )-.
• R e is -(CH 2 -CH 2 -0) 2 _6-R k , wherein R k is a linear or branched alkyl having 1 to 6 carbon atoms.
• V is -S- or -SS-.
• L' in the sixteenth or the seventeenth specific embodiment is represented by the following formula:
• r is an integer from 1 to 10
• Y is -H or -SO 3 M (e.g. , Y is -SO 3 M)
• M is -H or a pharmaceutically acceptable cation.
• the antibody is huMy9-6.
• L' in the sixteenth or the seventeenth specific embodiment is represented by the following formula:
• the conjugate is:
• r is an integer from 1 to 10
• Y is -H or -SO 3 M (e.g. , Y is -SO 3 M)
• M is -H or a pharmaceutically acceptable cation.
• the antibody is huMy9-6.
• R x is absent or selected from a linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
• R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g. , -NHR 101 ) or tertiary amino (-NR 101 R 102 ) group or a 5 or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R 101
• R are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms;
• Z s is linked to the CBA, and is either a bond, or -SR m -;
• R m is R d or a substituted linear or branched alkyl having 1 to 4 carbon atoms bearing a reactive ester, selected from N-hydroxysuccinimide esters, N- hydroxyphtalimide esters, N-hydroxy sulfo-succinimide esters, para-nitrophenyl esters, dinitrophenyl esters, and pentafluorophenyl esters;
• R d is selected from phenyl, nitrophenyl, dinitrophenyl,
• n is an integer from 1 to 24; and the remainder of the variables are as described above in the eighth or the fifteenth specific embodiment.
• R x is absent or selected from a linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
• R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g. , -NHR 101 ) or tertiary amino (-NR 101 R 102 ) group or a 5 or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R 101
• R are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms;
• n is an integer from 2 to 6;
• Z s is linked to the CBA, and is selected from:
• q is an integer from 1 to 5;
• M is -H or a cation, such as Na + or K + .
• Z s is represented by any one of the following formulas:
• W is -N(R 6 )-.
• R e is -(CH 2 -CH 2 -0) n -R k , wherein R k is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms.
• R k is -H or -Me
• n is 4, and q is 2.
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• R x is -(CH 2 ) p -(CR f R g )-, wherein R f and R g are each independently selected from H or a linear or branched alkyl having 1 to 4 carbon atoms; and p is 0, 1, 2 or 3.
• R f and R g are the same or different, and are selected from -H and -Me; and p is 1.
• the double line— between N and C represents a single bond or a double bond, provided that when it is a double bond X is absent and Y is -H, and when it is a single bond, X is -H; Y is -H, -OH or -S0 3 M (e.g. , Y is -OH or -S0 3 M);
• M is -H or a pharmaceutically acceptable cation (e.g. , Na + );
• X' and Y' are both -H;
• a and A' are both -0-;
• R 6 is -OMe
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• M is -H or Na + ;
• X' and Y' are both -H;
• a and A' are both -0-;
• R 6 is -OMe
• R x is a linear or branched alkyl having 1 to 6 carbon atoms.
• R x is -(CH 2 ) p -(CR f R g )-, wherein R f and R g are each independently selected from -H or a linear or branched alkyl having 1 to 4 carbon atoms; p is 0, 1, 2 or 3. More preferably, R f and R g are the same or different, and are selected from -H and - Me; and p is 1.
• X is -H
• Y is -H or selected from -OR, -OCOR' , -SR, - NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, - S0 3 M, -S0 2 M and a sulfate -OS0 3 M.
• Y is not -H.
• Y is selected from -H, -S0 3 M, -OH, -OMe, -OEt or - NHOH (e.g. , Y is -S0 3 M, -OH, -OMe, -OEt or -NHOH).
• Y is -H, -S0 3 M or -OH (e.g. , Y is -S0 3 M or -OH).
• M is -H, Na + or K + .
• Z and Z' when present, are -CH 2 -.
• X' is selected from the group consisting of -H, -OH, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, phenyl, the linking group, and an amine-protecting group.
• X' is -H, -OH, -Me or the linking group.
• X' is -H.
• Y' is selected from the group consisting of -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms.
• Y' is -H or oxo.
• Y' is -H.
• a and A' are the same or different, and are selected from -O- and -S-.
• a and A' are -0-.
• D and D' when present, are the same or different, and are independently selected from a polyethylene glycol unit (-OCH 2 CH 2 ) n , wherein n is an integer from 1 to 24, an amino acid, a peptide bearing 2 to 6 amino acids, or a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, wherein the alkyl, alkenyl and alkynyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR, -NR'COR", -SR and -COR'.
• a polyethylene glycol unit (-OCH 2 CH 2 ) n , wherein n is an integer from 1 to 24, an amino acid, a peptide bearing 2 to 6 amino acids, or a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, wherein the alkyl, al
• D and D' are linear or branched alkyl bearing 1 to 4 carbon atoms.
• conjugate of the present invention as described in the fourteenth, fifteenth, or the twenty-first specific embodiment is represented by the following:
• Y is -H
• R 3 is optionally the linking group and the other is -H;
• R 6 is -OMe
• Z and Z' are -CH 2 ;
• X' is -H
• Y' is -H
• a and A' are -0-.
• the conjugate of any one of the described embodiments may comprise 1-10 cytotoxic compounds, 2-9 cytotoxic compounds, 3-8 cytotoxic compounds, 4-7 cytotoxic compounds, or 5-6 cytotoxic compounds, each cytotoxic compound comprising the linking group linking the cytotoxic compound to the CBA, and each cytotoxic compound on the conjugate is the same.
• the cell-binding agent may bind to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing the CD4, CD6, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD56, EpCAM, CanAg, CALLA, or Her-2 antigens; Her-3 antigens; or cells expressing insulin growth factor receptor, epidermal growth factor receptor, and folate receptor.
• target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes
• the cell-binding agent may be an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, a domain antibody fragment that specifically binds to the target cell, a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, or a nutrient-transport molecule.
• the antibody may be a resurfaced antibody, a resurfaced single chain antibody, or a resurfaced antibody fragment.
• the antibody may be a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment thereof.
• the antibody may be a humanized antibody, a humanized single chain antibody, or a humanized antibody fragment.
• the invention further provides a pharmaceutical composition comprising any of the conjugates described herein, and a pharmaceutically acceptable carrier.
• the invention further provides a drug-linker compound comprising any of the subject compound covalently linked to a bifunctional linker.
• the invention additional provides a conjugate comprising any of the subject compounds, or the subject drug-linker compounds, linked to a cell-binding agent.
• the invention further provides a method of inhibiting abnormal cell growth or treating a proliferative disorder, an autoimmune disorder, destructive bone disorder, infectious disease, viral disease, fibrotic disease, neurodegenerative disorder, pancreatitis or kidney disease in a mammal comprising administering to the mammal a therapeutically effective amount of any of the compounds (with or without any linker group) or conjugates of the invention, and, optionally, a second chemotherapeutic agent.
• the compound or the conjugate is:
• r is an integer from 1 to 10
• Y is -H or -SO 3 M (e.g. , Y is -SO 3 M)
• M is -H or a pharmaceutically acceptable cation.
• the second chemo therapeutic agent is administered to the mammal sequentially or consecutively.
• the method is for treating a condition selected from cancer, rheumatoid arthritis, multiple sclerosis, graft versus host disease (GVHD), transplant rejection, lupus, myositis, infection, and immune deficiency.
• a condition selected from cancer, rheumatoid arthritis, multiple sclerosis, graft versus host disease (GVHD), transplant rejection, lupus, myositis, infection, and immune deficiency.
• the method or conjugate is for treating a cancer.
• the cancer is selected from breast cancer, colon cancer, brain cancer, prostate cancer, kidney cancer, pancreatic cancer, ovarian cancer, head and neck cancer, melanoma, colorectal cancer, gastric cancer, squamous cancer, small-cell lung cancer, non small-cell lung cancer, testicular cancer, Merkel cell carcinoma, glioblastoma, neuroblastoma, cancers of lymphatic organs and hematological malignancy including Leukemia (Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic lymphocytic leukemia (CLL), Chronic myelogenous leukemia (CML), Acute monocytic leukemia (AMOL), Hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (T-PLL), Large granular lymphocytic leukemia, Adult T-cell leukemia), Lymphoma (small lymphocytic lymphoma (SLL
• Lymphocyte depleted or not depleted Lymphocyte depleted or not depleted, and Nodular lymphocyte -predominant Hodgkin lymphoma), Non-Hodgkin's lymphomas (all subtypes), Chronic lymphocytic
• Lymphoplasmacytic lymphoma such as Waldenstrom macroglobulinemia
• Splenic marginal zone lymphoma Plasma cell neoplasms
• Plasma cell neoplasms Plasma cell neoplasms (Plasma cell myeloma, Plasmacytoma, Monoclonal immunoglobulin deposition diseases, Heavy chain diseases), Extranodal marginal zone B cell lymphoma (MALT lymphoma), Nodal marginal zone B cell lymphoma (NMZL), Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma, Mediastinal (thymic) large B cell lymphoma, Intravascular large B cell lymphoma, Primary effusion lymphoma, Burkitt lymphoma/leukemia, T cell
• prolymphocytic leukemia T cell large granular lymphocytic leukemia, Aggressive NK cell leukemia, Adult T cell leukemia/lymphoma, Extranodal NK/T cell lymphoma (nasal type), Enteropathy-type T cell lymphoma, Hepatosplenic T cell lymphoma, Blastic NK cell lymphoma, Mycosis fungoides / Sezary syndrome, Primary cutaneous CD30- positive T cell lymphoproliferative disorders, Primary cutaneous anaplastic large cell lymphoma, Lymphomatoid papulosis, Angioimmunoblastic T cell lymphoma, Peripheral T cell lymphoma (unspecified), Anaplastic large cell lymphoma), multiple myeloma (plasma cell myeloma or Kahler's disease).
• the cytotoxic compound may comprise a linking moiety with a reactive group bonded thereto.
• a bifunctional crosslinking reagent can be first reacted with the cytotoxic compound to provide the compound bearing a linking moiety with one reactive group bonded thereto (i.e., drug- linker compound), which can then react with a cell binding agent.
• one end of the bifunctional crosslinking reagent can first react with the cell binding agent to provide the cell binding agent bearing a linking moiety with one reactive group bonded thereto, which can then react with a cytotoxic compound.
• the linking moiety may contain a chemical bond that allows for the release of the cytotoxic moiety at a particular site.
• Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, peptidase labile bonds and esterase labile bonds (see for example US Patents 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073).
• Preferred are disulfide bonds, thioether and peptidase labile bonds.
• the compounds of formula (I)-(IV), (IA)-(IVA), and (IB)-(IVB) can be linked through Ri, R 2 , R 3 , P , RI ⁇ R 2 ⁇ R3 ' , 4' , L ⁇ L", L" ⁇ or X (when present).
• preferred linkable groups are R 2 ', R ', R 4 ', L', L", L' " and most preferred linkable groups are R 2 ', R 3 ', and L'. Examples of linking groups for compounds of formula (I)- (IV), (IA)-(IVA), and (IB)-(IVB) are described above.
• a solution of an antibody in aqueous buffer may be incubated with a molar excess of an antibody modifying agent such as N-succinimidyl- 3-(2-pyridyldithio)propionate (SPDP) or with N-succinimidyl-4-(2- pyridyldithio)butanoate (SPDB) to introduce dithiopyridyl groups.
• SPDP N-succinimidyl- 3-(2-pyridyldithio)propionate
• SPDB N-succinimidyl-4-(2- pyridyldithio)butanoate
• the modified antibody is then reacted with the thiol-containing cytotoxic compound, such as compound 2a, to produce a disulfide-linked antibody-indolinobenzodiazepine dimer conjugate.
• the cell binding agent-drug conjugate may then be purified using any purification methods known in the art, such as those
• the cell-binding agent-drug conjugate can be purified using tangential flow filtration, adsorptive chromatography, adsorptive filtration, selective precipitation, non-absorptive filtration or combination thereof.
• tangential flow filtration also known as cross flow filtration, ultrafiltration and diafiltration
• adsorptive chromatography resins are used for the purification of the conjugates.
• the antibody may be incubated with a molar excess of an antibody modifying agent such as 2-iminothiolane, L-homocysteine thiolactone (or derivatives), or N-succinimidyl-S-acetylthioacetate (SATA) to introduce sulfhydryl groups.
• an antibody modifying agent such as 2-iminothiolane, L-homocysteine thiolactone (or derivatives), or N-succinimidyl-S-acetylthioacetate (SATA) to introduce sulfhydryl groups.
• the modified antibody is then reacted with the appropriate disulfide-containing cytotoxic agent, to produce a disulfide-linked antibody-cytotoxic agent conjugate.
• the antibody- cytotoxic agent conjugate may then be purified by methods described above.
• the cell binding may also be engineered to introduce thiol moieties, such as cysteine-engineered antibodies disclosed in US Patent Nos.
• a solution of an antibody in aqueous buffer may be incubated with a molar excess of an antibody-modifying agent such as N-succinimidyl- 4-(N-maleimidomethyl)-cyclohexane-l-carboxylate to introduce maleimido groups, or with N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB) to introduce iodoacetyl groups.
• the modified antibody is then reacted with the thiol-containing cytotoxic agent to produce a thioether-linked antibody-cytotoxic conjugate.
• the antibody-cytotoxic conjugate may then be purified by methods described above.
• the number of cytotoxic molecules bound per antibody molecule can be determined spectrophotometrically by measuring the ratio of the absorbance at 280 nm and 330 nm.
• An average of 1-10 cytotoxic compounds/antibody molecule(s) can be linked by the methods described herein.
• the preferred average number of linked cytotoxic compounds per antibody molecule is 2-5, and the most preferred is 2.5-4.0.
• Cytotoxic agents containing linkers terminating in an N-hydroxy succinimidyl (NHS) ester can react with the antibody to produce direct amide linked conjugates such as huMy9-6-SPDB-lf or huMy9-6-BMPS-lf.
• the antibody-cytotoxic agent conjugate may then be purified by gel-filtration by any methods described above.
• FIGS. 22 and 23 Representative processes for preparing the cell-binding agent-drug conjugates of the present invention are shown in FIGS. 22 and 23.
• a cytotoxic dimer compound of the present invention can be conjugated with a cell binding agent through either a one- step or a two-step conjugation method.
• FIGs. 22a and 22b representative examples are described, wherein a dimer compound that possesses a linker such as an N- hydroxysuccinimide ester is reacted directly with a cell binding agent, such as an antibody, generating the desired conjugate.
• linkable dimer lg was first treated with sodium bisulfate to provide a modified dimer compound 26 before adding antibody to form the conjugate huMy9-6-SBDP-lf of the present invention.
• FIG. 23 A representative example of a two-step conjugation method is described in FIG. 23, wherein an antibody is first modified with a bifunctional crosslinking agent resulting in an antibody that possesses a desired number of linkers suitable for reaction with a dimer compound having a free thiol moiety.
• the antibody huMy9-6 was first modified with SPDB to give an antibody with linkers containing the dithiopyridyl moiety. The modified antibody was then exposed to a free thiol, such as 2a, generating the desired conjugate huMy9-6-SPDB-2a.
• W OH, OMe, ONHS, NHNH 2 , H, Me, Ph, Peptide
• Z" H, Me, SMe, S(CH 2 ) 3 C(0)NHS or CH 2 C(0)NHS or BMPS or SMCC or SPy or SPy-NO
• n 1 , 2 or 3
• W OH, OMe, ONHS, NHNH 2 , H, Me, Ph, Peptide
• Z" H, Me, SMe, S(CH 2 ) 3 C(0)NHS or CH 2 C(0)NHS or BMPS or SMCC or SPy or SPy-NO
• the cytotoxic compounds and cell-binding agent-drug conjugates of the invention can be evaluated for their ability to suppress proliferation of various cancer cell lines in vitro.
• cell lines such as the human colon carcinoma line COLO 205, the rhabdomyosarcoma cell line RH-30, and the multiple myeloma cell line MOLP-8 can be used for the assessment of cytotoxicity of these compounds and conjugates.
• Cells to be evaluated can be exposed to the compounds or conjugates for 1- 5 days and the surviving fractions of cells measured in direct assays by known methods. IC 50 values can then be calculated from the results of the assays.
• an in vitro cell line sensitivity screen such as the one described by the U.S.
• FIGS. 25-26 Examples of in vitro potency and target specificity of antibody-cytotoxic agent conjugates of the present invention are shown in FIGS. 25-26. All of the conjugates are extremely cytotoxic on the antigen positive cancer cells with an IC 50 in the low picomolar range. Antigen negative cell lines remained viable when exposed to the same conjugates.
• the indolinobenzodiazepine dimers showed target specific potency being 160 fold less potent when blocked with unconjugated antibody huMy9-6 (anti-CD33) and 40 less potent when blocked with unconjugated antibody FOLR1 (anti-folate receptor antibody).
• the huMy9-6-SPDB-lf conjugate is also highly potent towards both the HL60/ATCC cell line with an IC 50 value of 21 pM and the NB-4 cell line with an IC 50 value of 190 pM (FIGS. 25B and 25C).
• the present invention includes a composition (e.g., a pharmaceutical
• compositions comprising novel benzodiazepine compounds described herein (e.g., indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives thereof, or conjugates thereof, (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically acceptable carrier).
• the present invention also includes a composition (e.g., a pharmaceutical composition) comprising novel benzodiazepine compounds described herein, derivatives thereof, or conjugates thereof, (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically acceptable carrier), further comprising a second therapeutic agent.
• the present compositions are useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g.,
• compositions are also useful for treating depression, anxiety, stress, phobias, panic, dysphoria, psychiatric disorders, pain, and inflammatory diseases in a mammal (e.g., human).
• the present invention includes a method of inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g. , human) comprising administering to said mammal a therapeutically effective amount of novel benzodiazepine compounds described herein (e.g., indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives thereof, or conjugates thereof, (and/or solvates and salts thereof) or a composition thereof, alone or in combination with a second therapeutic agent.
• a mammal e.g., human
• novel benzodiazepine compounds described herein e.g., indolinobenzodiazepine or oxazolidinobenzodiazepine
• derivatives thereof or conjugates thereof, (and/or solvates and salts thereof) or a composition thereof, alone or in combination with a second therapeutic agent.
• the present invention also provides methods of treatment comprising administering to a subject in need of treatment an effective amount of any of the conjugates described above.
• the present invention provides a method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising any of the cytotoxic compound-cell-binding agents (e.g., indolinobenzodiazepine or
• the target cells are cells to which the cell-binding agent can bind.
• Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of ordinary skill in the art as the clinical situation warrants.
• Suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing or not containing about 1 mg/mL to 25 mg/mL human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose; and may also contain an antioxidant such as tryptamine and a stabilizing agent such as Tween 20.
• the method for inducing cell death in selected cell populations can be practiced in vitro, in vivo, or ex vivo.
• Examples of in vitro uses include treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells: treatments of bone marrow prior to their transplantation in order to kill competent T cells and prevent graft- versus-host-disease (GVHD); treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen.
• treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells treatments of bone marrow prior to their transplantation in order to kill competent T cells and prevent graft- versus-host-disease (GVHD); treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen.
• GVHD graft- versus-host-disease
• Examples of clinical ex vivo use are to remove tumor cells or lymphoid cells from bone marrow prior to autologous transplantation in cancer treatment or in treatment of autoimmune disease, or to remove T cells and other lymphoid cells from autologous or allogenic bone marrow or tissue prior to transplant in order to prevent GVHD.
• Treatment can be carried out as follows. Bone marrow is harvested from the patient or other individual and then incubated in medium containing serum to which is added the cytotoxic agent of the invention, concentrations range from about 10 ⁇ to 1 pM, for about 30 minutes to about 48 hours at about 37°C. The exact conditions of
• concentration and time of incubation i.e., the dose, are readily determined by one of ordinary skill in the art.
• the bone marrow cells are washed with medium containing serum and returned to the patient intravenously according to known methods.
• the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
• the cytotoxic agent of the invention will be supplied as a solution or a lyophilized powder that are tested for sterility and for endotoxin levels.
• suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 4 weeks as an intravenous bolus each week. Bolus doses are given in 50 to 1000 mL of normal saline to which 5 to 10 mL of human serum albumin can be added. Dosages will be 10 ⁇ g to 2000 mg per administration, intravenously (range of 100 ng to 20 mg/kg per day). After four weeks of treatment, the patient can continue to receive treatment on a weekly basis. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by one of ordinary skill in the art as the clinical situation warrants.
• Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of inducing cell death in selected cell populations include malignancy of any type including, for example, cancer of the lung (small cell and non-small cell), breast, colon, brain, prostate, kidney, pancreas, ovary, head and neck, skin (melanoma), Merkel cell carcinoma, glioblastoma, neuroblastoma, and cancers of lymphatic organs; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc.; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and others as determined by one of ordinary skill in the art.
• PDR Physician's Desk Reference
• the PDR discloses dosages of the agents that have been used in treatment of various cancers.
• the dosing regimen and dosages of these aforementioned chemotherapeutic drugs that are therapeutically effective will depend on the particular cancer being treated, the extent of the disease and other factors familiar to the physician of skill in the art and can be determined by the physician.
• the contents of the PDR are expressly incorporated herein in its entirety by reference.
• One of skill in the art can review the PDR, using one or more of the following parameters, to determine dosing regimen and dosages of the chemotherapeutic agents and conjugates that can be used in accordance with the teachings of this invention. These parameters include:
• cytotoxic agents [325]
• each of the cytotoxic agents described herein can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the starting compound.
• the skilled artisan will also understand that many of these compounds can be used in place of the cytotoxic agents described herein.
• the cytotoxic agents of the present invention include analogues and derivatives of the compounds described herein.
• the organic layer was dried over anhydrous sodium sulfate, filtered, concentrated and high vacuumed to give the mesylates as light yellowish oil (340 mg).
• the mesylates was transferred into a 10 mL round-bottomed flask with ethyl
• Triethylamine (5.41 mL, 38.8 mmol) and toluene sulfonyl chloride (3.17 g, 16.64 mmol) were added at 0 C.
• the reaction stirred for three hours at ambient temperature.
• the mixture was extracted with ethyl acetate and washed with brine.
• the organic extracts were dried with anhydrous sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (5% ethyl actetate/hexanes) resulted in 4-methyl-4- (methyldisulfanyl)pentyl 4-methylbenzenesulfonate (5c) (1.5g, 40%).
• 5b 1H NMR (400 Hz, CDC1 3 ): 53.42 (m, 2H), 2.19 (s, 3H), 1.77 (bs, 1H), 1.43 (m, 4H), 1.09 (s, 6H).
• the organic extracts were washed with ice water, dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the dimesylate.
• Compound lg was pre-treated with 3 molar equivalents of sodium bisulfite (using a freshly prepared NaHS0 3 solution in water) in 96-98% DMA in water for 4-5 hrs at 25 C.
• the humanized antibody at 2 mg/mL was reacted with 5-7 molar equivalents of compound lg (pre-treated with NaHSOs) for 6 h at 25 C in 85- 90% PBS, pH 7.4, aqueous buffer, or 50 mM HEPES, pH 8.5, aqueous buffer, containing 10-15% N,N-dimethylacetamide (DMA) and then purified over a G25 gel filtration column in PBS, pH 7.4, to remove unreacted or hydrolyzed drug compound.
• DMA N,N-dimethylacetamide
• the humanized antibody-SPDB-drug conjugates were dialyzed in 10 mM Histidine, 250 mM Glycine, 1% sucrose, pH 6.5 buffer.
• the Drug Antibody Ratio (DAR) of the conjugates were measured to be 2.2-2.9 by UV absorbance measurements at 280 and 320 nm and using the extinction coefficients of the drug and antibody at 280 nm
• the percentage of monomer in the conjugates were determined as >90% by SEC (Size Exclusion Chromatography) using TSK-Gel G300SWXL column (7.8 mm x 300 mm, 5 ⁇ particle size). Based on the UV absorbance of the monomer peak in SEC it was also demonstrated that the monomer conjugate peaks had linked drug molecules.
• SEC Size Exclusion Chromatography
• the conjugate was acetone extracted to remove protein, dried, and reconstituted in mobile phase and injected onto a VYDAC 208TP C8 reverse phase HPLC column (4.6 x 250 mm, 7 ⁇ particle size) and compared to standards.
• the percentage of free drug compound in the conjugate was determined as ⁇ 0.5% of conjugated drug compound. See FIG. 22.
• the LAR Linker Antibody Ratio
• the SPDB- modified antibody at 2 mg/mL was reacted with 2 molar equivalents of compound 2a (HC1 salt) per linked SPDB for 20 h at ambient temperature in 85% citrate buffer, 15 % DMA (v/v) and then purified over a G25 desalting column into PBS, pH 7.4 to remove unconjugated drug compound.
• conjugate was measured by UV spectrophotometry at 280 and 350 nm and calculated to be -1.7-2.1 DAR.
• the percentage of monomer and linked drug compound on the monomer in the conjugate was determined by HPLC using an SEC (size exclusion chromatography) column. See FIG. 23.
• COLO 205 1,000 cells/well
• Namalwa 3,000 cells/well
• HEL 92.1.7 3,000 cells/well
• RH30 1,000 cells/well
• HL60/QC 5,000 cells/well
• Ramos 10,000 cells/well
• KB 2,000 cells/well
• BJAB 2,000 cells/well
• NB4 3,000 cells/well
• RPMI 8226 8,000 cells/well
• cytotoxic potencies were then assessed using a WST-8 based cell viability assay and surviving cells were measured by developing with WST-8 (2-7 hours). The absorbance in each well was measured and the surviving fraction of cells at each concentration was plotted to reveal the cytotoxicity and/or antigen specificity (of the conjugates).
• unconjugated free drug compounds was measured against seven cell lines: KB, a HeLa cell contaminant, HL60/QC, an acute myeloid leukemia cell line, Namalwa, a Burkitt lymphoma cell line, NB4, an acute promyelocytic leukemia cell line, HEL92.1.7, an erythroleukemia cell line, RPMI8226, a multiple myeloma cell line and BJAB, a B-cell leukemia cell line.
• the results, shown in FIG. 24 and Table 10 demonstrate the high potency of these compounds across a wide range of cell types.
• the potency and specificity of the antibody-drug conjugates were measured against antigen-expressing cells, with and without the additions of an excess amount of blocking unconjugated antibody to show specificity of the killing effect.
• the MY9-6-drug conjugate was extremely potent towards three different antigen-expressing cells: HL60/ATCC, HL60/QC and NB-4, despite the very low antigen expression in NB4 cells.
• the specific potency could be blocked by addition of excess unconjugated antibody, demonstrating that the cell killing effect is antigen- specific.
• the huFOLRl-drug conjugate was effective in killing antigen-expressing KB cells in a specific manner. Results are illustrated in Figures 25 and 26.
• FIG. 44 Also see FIG. 49 for the potency of the various conjugates against various cell lines, expressed as IC 50 values (nM). Note that in FIGs. 25, 29, 34, 35, and 44, conjugagtes were prepared in the presence of sodium bisulfite.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Cell Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Indole Compounds (AREA)

Priority Applications (36)

Applications Claiming Priority (6)

Publications (1)

Family

ID=45755579

Family Applications (3)

Family Applications After (2)

Country Status (29)

Cited By (83)

Families Citing this family (85)

Citations (92)